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INTRODUCTION
ORAL DRUG DELIVERY SYSTEM
Oral drug delivery is the most desirable and preferred method of administering
therapeutic  agents  for  their  systemic  effects.  In  addition,  the  oral  medication  is
generally  considered  as  the  first  avenue  investigated  in  the  discovery  and
development of new drug entities and pharmaceutical formulations, mainly because of
patient acceptance, convenience, and cost effective manufacturing process. For many
drug  substances,  conventional  immediate  release  formulations  provide  clinically
effective  therapy  while  maintaining  the  required  balance  of  pharmacokinetic  and
pharmacodynamic  profiles  with acceptable  level  of  safety to  the patient  In  recent
years a  wide variety of newer oral  drug delivery systems like sustained/controlled
release dosage forms are designed and evaluated in order to overcome the limitations
of  conventional  therapy.  These  products  are  able  to  maintain  steady drug  plasma
levels for extended periods of time as a result the variations of the drug levels in the
blood are prevented and minimized drug related side effects.1
For many decades treatment of an acute disease or chronic illness has been
mostly  accomplished  by  delivery  of  drugs  to  the  patients  using  various
pharmaceutical dosage forms, including tablet, capsules, pills, suppositories, creams,
ointments,  liquids,  aerosols,  and  injectables,  as  drug  carriers.  Even  today  these
conventional  drug  delivery  systems  are  the  primary  pharmaceutical  product
commonly seen in the prescription and over- the counter drug market place. This
type  of  drug  delivery  system  is  known  to  provide  a  prompt  release  of  drug.
Therefore,  to  achieve  as  well  as  to  maintain  the  drug  concentration  within  the
therapeutically effective range needed for treatment, it is often necessary to take this
type  of  drug  delivery  system  several  times  a  day.  This  results  in  a  significant
fluctuation in drug levels.2
Recently, several technical advancements have been made. They have resulted
in the development of new technique for drug delivery. These techniques are capable
of controlling the rate of drug delivery, sustaining the duration of therapeutic activity,
and or targeting the drug to a tissue. Although these advancements have led to the
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developments  of  several  novel  drug  delivery systems  that  could  revolutionize  the
method of medication and provide a number of therapeutic benefits.
For  many  disease  states,  the  ideal  dosage  regimen  is  one  in  which  an
acceptable therapeutic concentration of the drug is immediately attained at the site of
action and is maintained constant for the desired duration of treatment. Conventional
dosage systems release the complete drug immediately after its administration. Their
kinetic pattern is as follows in figure 1.1.3
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 a                                                              Ke
   Dosage Form                Absorption Pool                          Target Area 
                          Drug               absorption              Elimination
release
                      Figure 1-1: Conventional order rate constants for drug release
These systems have limitations including 4
1. Plasma concentration fluctuations over successive dosing intervals.
2. For drugs having short biological half-lives, frequent doses are required to 
maintain the steady state plasma concentrations within the therapeutic range.
3. Thus, for such drugs, maintaining a therapeutic plasma concentration becomes a 
problem especially in the case of missing doses and the overnight no dose period.
4. The drug levels may not be within the therapeutic range at sufficiently early times.
This is an important consideration for certain disease states.
5. Patient noncompliance with a multiple dosing regimen can result in the failure of 
this therapeutic approach.
The  absorption  pool  has  drug  available  already  in  solution  and  ready  for
absorption at the site of absorption. The kr, ka, and ke are first order rate constants for
drug  release,  absorption,  and  overall  elimination,  respectively.  Immediate  release
from a conventional dosage forms has kr>>>ka. For non-immediate release dosage
forms kr << ka (i.e., the release of the drug from the dosage form is the rate limiting
step). The kinetic pattern is seen in Figure 1.2
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                               Drug release                                             elimination  
                              
                         Figure 1-2: Non immediate release dosage pattern
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Types of Non Immediate Release Dosage Forms4
A non-immediate release dosage form alters the release rate by affecting the
value of kr. A non- immediate release dosage form may be conveniently divided into
four categories: 
1) Delayed release
2) Sustained release 
            a)  Controlled release 
            b)  Prolonged release 
3) Site specific release 
4) Receptor release 
Delayed release employs a repetitive, intermittent dosing of drugs from one or
more immediate release units incorporated into a single dosage form. These types of
dosage forms include repeat  action tablets and capsules,  and enteric coated tablets
where timed release is achieved by barrier coating.
Sustained release dosages are drug delivery systems that achieve slow release
of the drug over an extended period of time. 
If the system is successful in sustaining a constant drug level in the body or
target tissue, it is considered a controlled release system.
If it is unsuccessful in providing a constant level, but extends the duration of action
over that which is achieved by conventional delivery, it is known as prolonged release
system. 
Site specific and receptor release refers to the targeting of a drug directly to a
certain biological  location. For site specific  release,  the target  should be a certain
organ or tissue. For receptor release, the target should be the particular receptor for a
drug within an organ or tissue.2
Oral Controlled release Drug Delivery Systems1
Oral  controlled  release  drug  delivery is  a  drug  delivery system that  provides  the
continuous  oral  delivery  of  drugs  at  predictable  and  reproducible  kinetics  for  a
predetermined period throughout the course of GI transit and also the system that
target the delivery of a drug to a specific region within the GI tract for either a local or
systemic action. All the pharmaceutical products formulated for systemic delivery via
the  oral  route  of  administration,  irrespective of  the mode of  delivery (immediate,
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sustained or controlled release) and the design of dosage form (solid, dispersion or
liquid),  must  be  developed  within  the  intrinsic  characteristics  of  GI  physiology.
Therefore the scientific framework required for the successful development of oral
drug delivery systems consists of basic understanding of
(i) physicochemical, pharmacokinetic and pharmacodynamics characteristics of the
drug;
(ii) The anatomic and physiologic characteristics of the gastrointestinal tract and 
(iii) Physicochemical characteristics and the drug delivery mode of the dosage form
to be designed.
The several advantages of a controlled drug delivery system over a conventional
dosage forms: 
• Total dose is low
• Reduced GI side effect
• Reduced dosing frequency
• Better patient acceptance and compliance
• Less fluctuation at plasma drug levels
• More uniform drug effect
• Improved efficacy/safety ratio
Disadvantages 
• Dose dumping
• Stability problem
• Reduced potential for accurate dose adjustment
• Need of additional patient education
The main areas of potential challenge in the development of oral controlled drug
delivery systems are: 1
• Development  of  a  drug  delivery  system:  To  develop  a  viable  oral  controlled
release drug delivery system capable  of  delivering a drug  at  a  therapeutically
effective rate to a desirable site for duration required for optimal treatment.
• Modulation of gastrointestinal transit time: To modulate the GI transit time so that
the drug delivery system developed can be transported to a target site or to the
vicinity of an absorption site and reside there for a prolonged period of time to
maximize the delivery of a drug dose. 
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• Minimization  of  hepatic  first  pass  elimination:  If  the  drug  to  be  delivered  is
subjected to extensive hepatic first-pass elimination, preventive measures should
be devised to either bypass or minimize the extent of hepatic metabolic effect.1  
ANATOMY AND PHYSIOLOGY OF GASTRO INTESTINAL TRACT AND
DRUG DELIVERY. 5
Systems used for the delivery of therapeutic agents via the oral route must be
designed conscious of the physiology of the gastrointestinal tract. The anatomy and
physiology of route of administration may dictate many of the requirements for the
systems.  For  example,  the  device  must  be  able  to  withstand  the  saliva,  as  saliva
contains digestive enzymes and other reagents for breaking down whatever is placed
in the mouth.  The stomach,  the  main digestive  organ of  the body,  contains many
digestive enzymes and very low pH. The pH of the stomach has been measured from
1.4 to 2.1.This harsh environment causes the destruction and denaturation of proteins
without protection. The pH of the stomach changes when food is present increasing to
nearly 4.0(Dressmanet al., 1990). 
Once through the harsh conditions of the stomach a device reaches the small
intestine, which is divided into three regions. The first region, closest to the stomach,
is  the duodenum, followed by the jejunum and ileum. The duodenum is about 10
inches in length, composes 5% of small intestine and jejunum composes 40% of the
length of the small intestine. The entire length of the small intestine is 5 meter and
residence time within the organ typically ranges from 2-4 h.
Microparticles smaller than 10 µm are transported to the payer’s patches of the
gut associated lymphoid tissue (GALT) (Eldridge  et al.,1990; Smith et al.,1995 and
Janiet al.,1992). The GALT is represented by the Payer’s patches (PPs), the appendix
and  small  solitary  lymphoid  nodules.  The  dome  regions  of  the  PPs  contains
lymphocytes,  macrophages  and  some plasma  cells  and  is  covered  by  the  follicle
associated epithelium which is specialised in the uptake of antigens from foods. The
cells responsible for the actual uptake of viruses, bacteria, toxins and microparticles
smaller  than 10 µm are  the  microfold cells  (M-cells)  (Lydyard  and Grossi,  1998;
Eldridge  et al., 1990). These M cells differ in morphology from absorptive cells by
their short microvilli, small cytoplasmic vesicles and few lysosomes.Fig1.3 gives an
overall idea about GIT and protein digesting enzymes involved in GIT.   
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Fig1.3 gives an overall idea about GIT.
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Human intestinal tract (lehninger principles of biochemistry, 2008).
The lining of the small intestine are composed of the serous, muscular, areolar,
and mucous layers. Only the mucous and areolar layers are the important layers with
respect to drug delivery. Transport of the nutrients into the body occurs through the
mucious cell layer and into the areolar layer where the nutrients are taken into the
blood stream. In the mucosal layer, there are cell layers that stick out of it and into the
open areas of the duodenum.
            Table 1.1: Gastro intestinal tract: Physical Dimension and Dynamics.
Drug Release from Controlled Oral Dosage Form .2
The  purpose  of  a  sustained  release  system  is  to  deliver  a  drug  at  a  rate
necessary to achieve and maintain a constant drug blood level. This means that the
rate of delivery should be independent of the amount of drug remaining in the dosage
form and constant over a certain time. It implies that the rate should follow zero order
kinetics. Zero order release may be theoretically desirable.  Non zero order release
rates may be clinically equivalent to constant release in many cases. 50
In order to achieve a therapeutic level promptly and maintain that level for a given
period of time, the dosage form generally should consist of two parts. 
With controlled oral dosage forms, the total drug in the dosage form should
consist of two portions, a loading dose and a maintenance dose. The initial loading
dose  is  released  immediately  on  its  administration.  The  release  of  the  drug  is
characterized by a first order kinetic process. The loading dose immediately obtains
the acceptable therapeutic plasma levels. The remaining dosage is released at a slow
Dept. of Pharmaceutics 7 JKKMMRF College of Pharmacy
Chapter I                                                                                                                Introduction
and a controlled rate in order to maintain the constant plasma concentration of the
drug. 
The release pattern has to follow zero order kinetics. Therefore, the rate of
release  of  the  drug  is  independent  of  the  remaining  fraction  of  the  dose.  The
controlled oral dosage form involves releasing the maintenance dosage at a rate which
is equivalent to the elimination rate of the drug. 
Methods of Preparing Controlled Oral Dosage Forms 
A number  of  formulation  methods  have  been  developed  to  overcome  the
barrier seen with immediate release oral dosage forms. These processes include: inert
insoluble matrices; use of coatings; hydrophilic matrices; as well as the combination
of hydrophilic and hydrophobic polymers (5);  embedding of the drug in a wax or
plastic  matrix;  ion  exchange  resins;  osmotic  pumps;  and  microencapsulation.  The
physiology of the gastrointestinal tract, the physico-chemical property of the drug, the
drug release pattern, the pharmacological action of the drug, is parameters that must
be considered. The 6 physico-chemical properties of the drug involve such parameters
as: aqueous solubility; stability; pKa and permeability values.2
The Biopharmaceutical Classification System (BCS) involves placing a drug into
four classifications (6): 1
1. High solubility and high permeability 
2. Low solubility and high permeability 
3. High solubility and low permeability 
4. Low solubility and low permeability
Class 1 is considered the preferred category while Class 4 is the worst category. A
drug having high solubility in the intestine is a good drug for a controlled oral dosage
form. The drug permeability value must also be considered and should be more than
the prescribed value. The drug having a biological half-life of between two and six
hours is the preferred drug because we want to avoid accumulation of the drug in the
body. 
Multiparticulate dosage form2
Multiparticulate dosage form contains actives divided into many individual
units, so-called subunits, each exhibiting some desired characteristics. These subunits
usually  are  microparts  such  as  microcapsules,  microspheres,  lipospheres,
microgranules or  larger  particles  -  pellets.  Multiparticulate dosage forms are more
expensive  to  manufacture  and  develop,  but  despite  of  it  are  widely  used  in
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pharmaceutical  formulations.  They  are  more  reliable  in  their  biopharmaceutical
behavior and considered to provide pharmacokinetic advantages compared
With monolithic dosage forms 
When compared  with  single-unit  dosage  forms,  oral  multiparticulate  drug-
delivery systems offer biopharmaceutical advantages: 
• Micro particles can be used to prepare pharmaceutical formulations composed of
Incompatible drugs or to obtain delivery systems with different release profiles.
• Can be divided into desired doses without formulation and process changes.
•  Possibility to produce modified release dosage forms as very significant means of
drug delivery now a day.
• More even and predictable distribution and transportation in the gastrointestinal
tract,  which  is  fairly  independent  of  the  nutritional  state  .When  taken  orally
multiparticulates  generally  disperse  freely  in  the  gastrointestinal  tract,  thus
maximize drug absorption, reduce peak plasma fluctuation, minimize side effects
and reduce inter and intra patient variability 
• Are  less  susceptible  to  dose  dumping  than  the  reservoir-type,  single  unit
formulations.  These  dosage  forms have  several  disadvantages,  like  the  risk of
tampering with capsules or
The  rupturing  of  the  coating  during  compression  resulting  in  a  loss  of  the
modified drug-release Properties .6          
Two general structures exists – Microcapsules and Microparticles1
Microcapsules are a  system that  contains  a  well-defined core and a well-
defined envelop. The core can be solid, liquid or gas; the envelope is a made of a
continuous,  porous  or  non-porous,  polymeric  phase.  The  drug  can  be  dispersed
inside the microcapsule as solid particulates with regular or irregular shapes, pure or
dissolved  solution,  suspension,  emulsion  or  a  combination  of  suspension  and
emulsion.1
A micro particle is a structure made of a continuous phase of one or more
miscible polymers in which particulate drug are dispersed at either the macroscopic
or molecular levels. However, difference between the two systems is the nature of
the micro particle matrix in which no well -defined wall or envelop exists.
Dept. of Pharmaceutics 9 JKKMMRF College of Pharmacy
Chapter I                                                                                                                Introduction
The term microcapsule is defined as a spherical particle with size varying from
50nm  to  2  mm,  containing  a  core  substance.  Microspheres  are  in  strict  sense,
spherically empty particle. However, the term microcapsule and microsphere are often
used synonymously. In addition, some related terms are used as well. For example
“microbeads” and beads are used alternatively.
Microencapsulation  has  become  a  common  technique  in  the  production  of
controlled release dosage forms. One approach for controlled release formulation of
different therapeutic agents is the production of polymeric gel beads. The beads are
discrete spherical microcapsules that serve as the solid substrate on which the drug is
coated or encapsulated in the core of the beads. Beads can provide sustained release
properties and more uniform distribution of drugs include, within the gastrointestinal
tract. Furthermore, bioavailability of drugs formulated in beads has been enhanced.
Numerous  studies  have  been  reported,  concerning  the  use  of  alginate  beads  as  a
controlled release carrier. Formulation of cardiovascular drug in beads forms could
reduce its dosing frequency. Hence, in this study the formulation of Calcium alginate
cardiovascular drug beads, through ionotropic gelation and cross linking method has
been investigated. 7
On the basis of classification these microcapsules and microspheres are prepared
by following techniques:
• Single emulsion technique 
• Double emulsion technique 
• Polymerization technique 
• Normal polymerization technique 
• Interfacial polymerization technique 
• Phase separation coacervation technique 
• Spray drying & spray congealing technique 
• Solvent extraction technique 
• Solvent evaporation technique 
• Solvent diffusion technique 
• Ionotropic gelation technique 
 Release characteristics of gel beads 8 
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Release of core material from non-erodible microbeads can occur in several
ways. Non-erodible spherical microbeads release the encapsulated material by steady-
state diffusion through a coating of uniform thickness. The rate of release remains
constant  as  long  as  the  internal  and  external  concentration  of  core  material  and
concentration  gradient  through  the  membrane  are  constant.  If  some  of  the
encapsulated material migrates through the microcapsule membrane during storage a
burst  effect occurs. If  the microcapsule acts as inert  matrix particle in which core
material is dispersed (microparticles) the Higuchi model is valid up to 60% release.
Microencapsulation by Ionotropic Gelation Technique
In this method strong spherical beads with a narrow particle size distribution
and low friability could be prepared with high yield and a drug content approaching
91.25  %.  The  flow  properties  of  micronized  or  needle  like  drug  crystals  were
significantly improved by this agglomeration technique when compared with non-
agglomerated  drug  crystals.  The  ionic  character  of  the  polymers  results  from pH
dependent disintegration of the beads.6
One of the most important and useful properties of alginates is the ability to
form gels by reaction with calcium salts. Alginic acid is composed of D-mannuronic
acid  and L-gluronic  acid residues  at  varying proportions  of  GG-,  MM- and  MG-
blocks. Crosslinking takes place only between the carboxylate residue of GG-blocks
and Ca+2  ions via egg-box model to give a tight gel network structure. These gels
resemble a solid in retaining their shape and resisting stress and consist of almost
100% water. 
A gel in classical colloidal terminology is defined as a system which owes its
characteristic properties to a cross-linked network of polymer chains which form at
the gel point. A considerable amount of research has been carried out in recent years
to elucidate the nature of the cross-links and determine the structure of alginate gels. 
It has been suggested that the cross-links were caused either by simple ionic bridging
of two carboxyl groups on adjacent polymer chains via calcium ions or by chelating
of a single calcium ions by hydroxyl and carboxyl groups on each of a pair of polymer
chains.4
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Polymers used for the preparation of microbeads.8
A  number  of  Different  substances  both  biodegradable  as  well  as  non-
biodegradable  have  been  investigated  for  the  preparation  of  microbeads.  These
materials  include  the  polymers  of  natural  and  synthetic  origin  and  also  modified
natural  substances.  Some  examples  of  polymers  are  Albumin,  Gelatin,  Sodium
alginate, Chitosan, Starch, Dextran, Poly lactide and olyglycolide
Polyanhydride, Polyphosphazene etc.
Sodium alginate micro beads
Beads are one of the multiparticulate drug delivery systems and are prepared
to obtain prolonged or controlled drug delivery, to improve bioavailability or stability
and to target drug to specific sites. Multiple unit dosage forms such as microspheres
or beads have gained in popularity as oral drug delivery systems because of more
uniform distribution  of  the  drug in  the   gastrointestinal  tract,  more  uniform drug
absorption, reduced local irritation and elimination of unwanted intestinal retention of
polymeric material, when compared to non-disintegrating single unit dosage form.9
Beads can also offer advantages like
• Limiting fluctuation within therapeutic range,
• Reducing side effects,
• Decreasing dosing frequency.
• Improving bioavailability.
• Improving patient compliance.
Alginates are naturally occurring polysaccharides obtained mainly from marine
brown algae belonging to the Phaeophyceae, composed of two monomeric units, β-D-
mannuronic  acid  and  α-L-guluronic  acid.  Alginate  salts  are  known  to  form  a
reticulated structure when in contact with calcium ions and this characteristic has been
used to produce sustained release particulate systems for a variety of drugs, proteins
and  even  cells.  The  gel  forming  ability  is  related  mainly  to  the  proportion  and
arrangements of mannuronic to guluronic acid units present. Calcium Alginate beads
can  be  produced  by dropping  a  sodium alginate  aqueous  solution  into  a  calcium
chloride solution. Although this is a simple and fast way of obtaining particulate drug
carriers, the method presents a major limitation consisting of drug loss during bead
preparation. In addition, the calcium alginate matrix formed is usually very permeable
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and little or no drug release can actually be controlled in the case of soluble drugs [4,
5]. Hence, a preferential use for alginate gel beads in the delivery of low solubility or
macromolecular  drugs  has  been  suggested,  while  some  researchers  were  able  to
circumvent  this  problem by  mixing  alginate  with  other  polymers  such  as  pectin,
chitosan, ethyl cellulose and Eudragit. Successful attempts involving the cross-linking
of sodium alginate alone or with albumin or gelatin, using aldehydes, have also been
reported. However, the techniques utilized in these studies either may cause a high
degree of particle aggregation or involve the use of methanol as a solvent.10
Gelation Properties 4
In the presence of certain divalent and multivalent cations. For example Ca2+,
alginates form gels. The properties of these gels depends upon the mannuronic acid to
guluronic acid ratio (M: G ratio) of the alginate. Alginates with a high guluronic acid
content Form strong brittle gels, whereas those with a high mannuronic acid content
form weaker but more flexible gels. There are only minor differences in the structure
of the two monomers and their affinity for divalent cations, thus the large difference
seen in ion-binding by poly-guluronate and poly-mannuronate groups must have a
macromolecular  explanation.   In  order  that  the  bulky  carboxyl  group  is  in  the
energetically favored equatorial  position,  the two uronic acids will  adopt different
preferred conformations. Thus, mannuronic acid adopts the 4C 1 chair conformation
and guluronic acid adopts the lC4 boat form Evidence from X-ray diffraction studies
supports this theory.
Figure 1.4 Gelation properties of sodium alginate
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The orientation of the glycosidic bonds between the monomers will then affect
the conformation of the polysaccharide chain. Therefore, it has been predicted (Rees
1972), that regions in which poly-D- mannuronate predominates (M-M-M) will form
an extended ribbon structure (Figure 1.4), similar to that of cellulose. Whereas, the
region in which poly-L-guluronate predominates (G-G-G) will form a buckled chain
(Figure 1.4). Further X-ray diffraction experiments by Atkins et al (l973a and 1973b);
together with solution studies using 1H-NMR (Penman and Sanderson 1972),  and
13C-NMR (Grasdalen et al 1977) provide evidence to confirm this prediction. 
The mode of binding of Cations by the various block structures within the
alginate explains why the gels formed have different properties depending on the ratio
of  D-mannuronate to L-guluronate  (M:G ratio).   All  the block structures  are poly
anionic and will form intermolecular bonds with divalent or multivalent cations, such
as  Ca2+.  However,  poly-guluronate regions are also able to chelate the metal  ion
because of the spatial arrangement of the ring and hydroxyl oxygen atoms, there by
forming a much stronger type of interaction. Cavity-like sites are formed between
adjacent G-units into which ions such as Ca2+ fit well (Figure 1.6). Thus, two or more
chains may be joined together, side by side, by salt bridge formation Between  the G-
blocks. This has been likened to the cross-section of an 'egg-box' (Grant et al 1973) as
shown in Figure 1.7, where the Ca2+ ions are the 'eggs' within the 'egg-box'-like cross
section of the alginate chains.
For this reason, when controlled amounts of calcium are added to alginate
solutions, gels are formed. The calcium ions bind strongly to the G-blocks, but the
formation of an insoluble precipitate is prevented by the presence of the M -blocks
and  the  MG-blocks  where  the  interaction  with  calcium  ions  is  less.  Since  most
alginates contain all three types of block structure (M, G, and MG), a classical gel
structure  can  be  formed  where  the  G-blocks  from  the  junction  zones  which  are
terminated by regions of M-blocks or MG-blocks. These remain dissolved and keep
the system in solution as a hydrated three-dimensional network. There by
Forming a gel. 
Extraction and Preparation:  Since alginates occur in the form of insoluble
calcium, magnesium, sodium and potassium salts contained in the algal cell walls and
the  extra  cellular  matrix,  their  extraction  and  purification  generally  involve  ion
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exchange techniques;  the details of the extraction methods are given in figure 1.5.
Generally  to  prepare  alginates  for  commercial  use,  the  algae  is  mechanically
harvested  and  dried  before  further  processing  except  for  M.  Pyrifera  which  is
processed in wet. Alginates are then extracted from dried and milled algal material
after treatment with dilute mineral acid to remove or degrade associated neutral homo
polysaccharides  such  as  laminarin  and  fucoidin.  Concurrently  the  alkaline  earth
cations  are  exchanged  for  H+.  The  alginate  is  then  converted  from the  insoluble
proteonated form to the soluble sodium salt by addition of sodium carbonate at a PH
below 10. After extraction, the alginate can be further purified and then converted to
either a salt or acid .
Therapeutic applications of sodium alginate beads.10
The alginate, chitosan or alginate-chitosan beads can have various therapeutic 
uses depending upon the drug loaded into them.
1. NSAIDs like Diclofenac sodium may be made into beads which show reduced
release in the acidic environment of the stomach. This minimizes the adverse
effects of oral administration and avoids direct contact between the drug and the
gastric mucosa. ] The other NSAID, ibuprofen, may also be the candidate for the
prolonged and the controlled release formulation because of its short half- life
and gastric irritation activity both of which can easily be overcome by using the
alginate beads.
2. The beads loaded with the antibiotics (like ampicillin) may be useful for the oral
delivery for the treatment of gastric and intestinal diseases. The sustained and the
controlled release of ampicillin may be useful to overcome its short biological
half-life of 0.75-1.5 hours.
3. Antihypertensive drugs, like verapamil HCl, with low bioavailability due to first
pass metabolism may be formulated in the alginate chitosan beads so that their
controlled release may be obtained for the prolonged therapeutic effect.  Another
antihypertensive calcium channel blocker, Nicardipine, may be a candidate for
the controlled release beads as it has a very short half- life of 1 hour.
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4. The sustained release dosage form which delivers melatonin over the period of 8
hours may be useful for those who have disordered circardian rhythm and that
could be maintained through the use of polymer reinforced and coated alginate
beads.  Melatonin has short half- life so is not very effective as immediate release
dosage form
5. Sustained  release  of  prednisolone  from  chitosan  gel  beads  allows  minimum
effective dose to be delivered locally (subcutaneous) and prolongs the duration of
drug activity. So, it improves the therapeutic efficacy and decreases side effects
by minimizing the transportation of the drug to the systemic circulation against
inflammation. 
6. Theophylline,  a poorly water soluble bronchodilator and the targeted drug for
sustained  delivery,  showed  the  retarded  drug  release  under  physiologically
simulated pH conditions (acidic and neutral).  So, it could be a good candidate
for the modified dosage forms
7. Ketoconazole, an antifungal drug, may be formulated into the polymeric beads to
reduce the adverse effects like hepatic dysfunction and GI disturbances which are
generally observed with conventional oral dosage forms. 
8. Cefadroxil,  an  antibiotic  used  in  the  treatment  of  bacterial  infections,  has  a
biological half-life of 1.2-2.0 hours. Its short half-life may be enhanced by the
use of the sodium alginate interpenetrating network beads.
9. Insulin, an anti-diabetic polypeptide drug, and albumin are degraded in the acidic
medium when given orally. Formulating them in the modified alginate beads may
deliver  them  in  the  intestinal  region  without  significant  degradation  in  the
stomach.
10. Brilliant  blue  (poorly  water  soluble  dye)  showed  the  extended  release  and
dextran (water soluble polysaccharide) showed a faster release indicating that the
water insoluble drugs may be used for the controlled delivery.
11. Alginate-chitosan  beads  containing  nicotinic  acid  and  ascorbic  acid  (a  water
soluble  vitamin),  drugs  for  hyperlipidemia,  show  controlled  release  of  these
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drugs. Bile acids are responsible for the breakdown and the absorption of the
fatty substances. The beads may also be useful in absorbing the bile acids and
may prove to be very valuable in treatment of hyperlipidemic patients. 
12. Unpredictable  and  incomplete  absorption  limits  the  oral  delivery  of  5-
fluorouracil,  an anticancer  drug.  So their  local  use in  the treatment  of  breast
cancer may be justified in polymeric bead forms.
13. Metronidazole,  an antiulcer  drug,  in  bead form to be retained in stomach for
sufficient time to exert anti Helicobactor pylori effect. The gastro-retention of the
drugs, especially antiulcer and antacid, by formulating them in the floating beads,
could open new doors for the treatment of gastric ulcer and acidity.
Gastric emptying:
            The process of gastric emptying occurs during fasting as well as fed states.
However, the pattern of motility is distinct in the 2 states. In the fasting state, it is
characterized by an interdigestive series of electrical events that cycle both through
stomach  and  small  intestine  every  2  to  3  hours  11.   This  activity  is  called  the
interdigestive myloelectric cycle or migrating myloelectric cycle (MMC), which is
further  divided  into  following  4  consecutive  phases  as  described  by  Wilson  and
Washington12. 
Phase I (basal phase): it is a quiescent period lasting from 40 to 60 minutes
with rare contractions.
Phase II (preburst phase): it is period of similar duration lasting for 40 to 60
minutes  consisting of  intermittent  action potentials  and contractions that  gradually
increases in intensity and frequency as the phase progresses.
Phase  III  (burst  phase):  it  is  a  short  period  of  intense,  large  regular
contractions lasting for r 4 to 6 minutes. It is this phase, which gives the cycle the
term, housekeeping wave, since it  serves to sweep undigested materials out of the
stomach and down the small intestine.
             As phase III of one cycle reaches the end of the small intestine, phase III of
the next cycle starts I the duodenum.
Phase IV:  it is a brief transitional phase that occurs between phase III and
phase I of their two Consecutive cycles. The motor activity in the fed state is induced
5-10 min after ingestion of a meal and persists as long as food remains in the stomach.
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It consists of regular and frequent contractions. These contractions are not as severe as
those in the third phase of the fasted motility pattern 13.
Fig.2.Schematic representation of interdigestive motility.
                   
1.4: Factors Affecting Gastric Retention.
Density:  GRT is a function of dosage form buoyancy that is dependent on the
density of a dosage form which affects the gastric emptying rate. A buoyant dosage
form should have a density of less than that of the gastric fluids floats. Since it is
away from the pyloric  sphincter,  the dosage unit  is  retained in the  stomach for  a
prolonged period.
Size:  Dosage form units having a diameter of more than 7.5 mm are reported
to have an increased gastric residence time compared with those having a diameter of
9.9  mm.  Gastric  retention  time  of  an  dosage  form  in  the  fed  state  can  also  be
influenced by its size. Small tablets are emptied from the stomach during the digestive
phase while large .size units are expelled during the house keeping waves 14,15.
Shape of dosage form: The six shapes tested (ring, tetrahedron, cloverleaf,
disk, string and pellet) displayed different gastric retention times, due to their size and
geometry of the systems 16,.The tetrahedron resided in the stomach for longer periods
than other devices of a similar size; likewise extended gastric retention was observed
with rigid rings .Tetrahedron and ring-shaped devices with a flexural modulus of 48
and 22.5 kilo pounds per square inch (KSI) have a better gastric residence time as
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compared with other shapes and had been reported to have better GRT 90% to 100%
retention at 24 hours compared with other shapes.
Single  or multiple  unit  formulation:   multiple  unit  formulations  show a
more predictable release profile and insignificant impairing of performance due to
failure  of  units,  allow co-administration of  units  with  different  release  profiles  or
containing  incompatible  substances  and  permit  a  larger  margin  of  safety  against
dosage form failure compared with single unit dosage forms.
Effect of buoyancy: On comparison of floating and nonfloating dosage units,
it  was concluded that  regardless  of  their  sizes  the  floating dosage  units  remained
buoyant on the gastric contents throughout their residence in the gastrointestinal tract,
while  the  nonfloating  dosage  units  sank  and  remained  in  the  lower  part  of  the
stomach. Floating units away from the gastro-duodenal junction were protected from
the peristaltic waves during digestive phase while the nonfloating forms stayed close
to the pylorus and were subjected to propelling and retropelling waves of the digestive
phase. 
FOOD HABITS AFFECT THE GRT IN THE FOLLOWING WAYS:
Fed or unfed state: under fasting conditions, the GI motility is characterized
by periods of strong motor activity or the migrating myloelectric complex (MMC)
that  occurs  every 1.5 to  2 hours.  The MMC sweeps undigested material  from the
stomach and, if the timing of administration of the formulation coincides with that of
the MMC, the GRT of the unit can be expected to be very short. However, in the fed
state,  MMC is  delayed and GRT is  considerably longer.  It  was concluded that  as
meals were given at the time when the previous digestive phase had not completed,
the floating form buoyant in the stomach could retain its position for another digestive
phase as it was carried by the peristaltic waves in the upper part of the stomach.
Nature  of  meal: feeding  of  indigestible  polymers  or  fatty  acid  salts  can
change the motility pattern of the stomach to a fed state, thus decreasing the gastric
emptying rate and prolonging drug release.
Caloric content: GRT can be increased by four to 10 hours with a meal that is
high in proteins and fats.
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Frequency  of  feed:  the  GRT  can  increase  by  over  400  minutes  when
successive meals are given compared with a single meal due to the low frequency of
MMC.
Gender: mean  ambulatory GRT in  males  (3.4±0.6hours)  is  less  compared
with their age and race matched female counterparts (4.6±1.2 hours), regardless of the
weight, height and body surface 17.
Age: elderly people, especially those over 70, have a significantly longer GRT.
Posture: GRT can vary between supine and upright ambulatory states of the
patient.  When subjects  were  kept  in  the  supine  position it  was  observed  that  the
floating  forms  could  only prolong  their  stay because  of  their  size;  otherwise  the
buoyancy remained no longer an advantage for gastric retention.
Biological factors: diabetes and Crohn.s disease, Etc.
Concomitant  Drug  administration  &  interaction:  anticholinergics  like
atropine  and  propantheline,  opiates  like  codeine  and  prokinetic  agents  like
metoclopramide and cisapride.
In  order  for  a  hydrodynamically  balanced  dosage  forms  to  float  in  the
stomach. The density if the dosage forms should be less than the gastric contents.
However,  the floating force kinetics of such dosage form has shown that the bulk
density of  a  dosage  form is  not  the  most  appropriate  parameter  for  describing its
buoyant  capabilities14.  The  prolongation  of  the  gastric  residence  time by food  is
expected to maximize during drug absorption from the dosage form due to increased
dissolution of the drug and longer residence at the most favourable sites of absorption.
However, literature data on the relationship between device size and gastric residence
time are contradictory 18-20.
1.5 : Absorption window:
The G.I tract offers a varied environment capable of affecting the absorption
of poorly administered drugs .Anatomical features, physiological phenomenon, and
nature  of  gastrointestinal  milieu  contributes  these  changes.  This  can  lead  to  the
variations  in  the  intestinal  permeability  of  drug  molecules,  resulting  in  the
phenomenon of Absorption window, where in the drug is preferentially absorbed only
from a particular region of the G.I.tract.
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Fig.3.  Absorption window in G.I. tract.
1.5.1. ABSORPTION WINDOW COULD RESULT FROM THE FOLLOWING
FACTORS:
1.5.1.1. Physico-chemcal factors:
PH- dependent solubility and stability:
          A drug experiences a pH range of 1-8 across the G.I tract and needs to be in
solubilised form to successfully cross the biological membrane. Most of the drugs are
passively absorbed, in their un-ionized form and the extant of ionization at different
pH dependent solubility, stability and ionization by changing the physical properties
of the drug in different portions of the G.I tract, can lead to regional variability in
absorption of drugs.
1.5.1.2. Physiological factors:
(a). Mechanism of absorption:
                  Perorally administered drugs are absorbed both by passive diffusion as
well as by nonpassive means of absorption. Drugs absorbed by active and facilitated
transport mechanisms show higher regional specificity due to the prevalence of these
mechanisms only in a particular region of G.I tract.
(b). Metabolic Enzymes:
       Presence of certain enzymes in a particular region of G.I tract can also lead to
regional  variability  in  absorption  of  drugs  that  are  substrates  to  those  enzymes.
Intestinal  metabolic  enzymes  principally,  phase  one  metabolizers  like  cytochrome
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P450 are  abundantly  present  in  the  intestinal  epithelium.  Their  activity  decreases
longitudinally  along  the  small  intestine,  with  the  levels  rising  slightly  from  the
duodenum to  the  jejunum and  then  declining  in  the  ileum  and  colon.  This  non-
uniform distribution of cytochrome P450 causes regional variability in the absorption
of drugs that are substrate to these enzymes.
1.6: Gastric retention Systems:
                Is a device, which resides in the confines of the stomach over a prolonged
period of time (prolonging the residence time of the drug delivery system) for the
purpose of providing a platform for controlled release of biologically active agents.
The system releases the active agent to be absorbed or released from the stomach to
be absorbed in the upper parts of the small intestine. In particular it allows for less
frequent  dosing  of  the  active  agent  than  with  immediate  release  formulations  or
sustained released formulations that are not gastric retentive dosage forms. In other
applications the frequency of dosing may be the same, but the gastric retention dosage
forms  will  beneficially  alter  the  absorption  profile  of  the  active  agent  from that
available  with  immediate  release  formulations.  This  may  result  in  increased
bioavailability of the active agent with reduced side effects 21.
Over the last three decades, a various approaches have been pursued to prolong the
residence time of a an oral dosage forms in the stomach, these methods include
• Floating systems 22
• Swelling and expanding systems 23,24
• Bioadhesive systems 25,26
• Modified- shape systems 27
• High density systems 28,29
• Other gastric emptying devices 30
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Fig.4. Different approaches of gastric retention
Peptic ulcer
A peptic  ulcer,  also  known  as PUD or peptic  ulcer  disease,[] is  the  most
common ulcer of an area of the gastrointestinal  tract that is  usually acidic and thus
extremely painful. It is defined as mucosal erosions equal to or greater than 0.5 cm.
As many as 70–90% of such ulcers are associated with Helicobacter pylori, a spiral-
shaped bacterium that lives in the acidic environment of the stomach; however, only
40% of those cases go to a doctor. Ulcers can also be caused or worsened by drugs
such as aspirin, ibuprofen, and other NSAIDs.
Four times  as  many peptic  ulcers  arise  in  the duodenum—the first  part  of
the small  intestine,  just  after  the  stomach—as  in  the stomachitself.  About  4%  of
gastric ulcers are caused by a malignant tumor,  so multiple biopsies are needed to
exclude cancer. Duodenal ulcers are generally benign.
Gastroesophageal reflux disease
Gastroesophageal  reflux  disease (GERD), gastro-oesophageal  reflux
disease (GORD), gastric reflux disease, or acid reflux disease is a chronic symptom
of mucosal damage  caused  by  stomach  acid  coming  up  from  the stomach into
the esophagus.[1] Informally called heartburn.
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GERD is usually caused by changes in the barrier between the stomach and
the  esophagus,  including  abnormal  relaxation  of  the lower  esophageal  sphincter,
which normally holds the top of the stomach closed; impaired expulsion of gastric
reflux from the esophagus,  or ahiatal  hernia.  These changes may be permanent or
temporary ("transient").
Another kind of acid reflux, which causes respiratory and laryngeal signs and
symptoms,  is  called laryngopharyngeal  reflux (LPR)  or  "extraesophageal  reflux
disease"  (EERD).  Unlike  GERD,  LPR  is  unlikely  to  produce  heartburn,  and  is
sometimes called silent reflux.
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REVIEW OF LITERATURE
Nicole M.  et al., (1991)  studied the effect of simultaneous modification of medium
composition and growth conditions on the production of Lactococcus lactis subsp.
cremoris  biomass  in  calcium alginate  beads  was  studied  by  the  response  surface
method.  Statistical  methods  of  data  analysis  for  unbalanced  experiments  are
illustrated. The media tested were whey, whey supplemented with yeast extract and/or
meat  extract,  milk,  and  the  commercial  medium  Gold  Complete  (Nordica).
Fermentations were performed at 23°C under pH control (5.6, 6.0, 6.4, or 6.8). In one
complete  series,  1% CaCO3 was  added  to  the  growth  media.  There  were  strong
interactions between CaCO3 and media, CaCO3 and pH level, and CaCO3, media,
and pH level. In media with CaC03, all first-order interactions between media, pH,
and sampling time were significant. The addition of CaCO3 increased cell counts in
whey-meat extract medium, but no significant difference was found with the other
media. Uncoupling between growth and acidification occurred between 16 and 22 h.
Highest counts were obtained on milk and Gold Complete (6 x 1010/g). In CaCO3-
containing media, pH influenced cell counts only in whey and in Gold Complete (pH
5.6 and 6.0 giving the best results); pH also influenced the bead mass obtained at the
end of the fermentation. Biomass production in alginate gels is proposed as a method
of obtaining concentrated cell suspensions without centrifugation or filtration. 
Methal A. et al., (2000) prepared anti-hapten IgG that was covalently immobilized on
glutaraldehyde to prepared alginate-chitosan gel beads. The antibody immobilization
efficiency was influenced by glutaraldehyde-bead reaction time, IgG concentration
and pH. In addition, immobilization conditions such as glutaraldehyde and antibody
concentrations influenced antibody hapten binding affinity. The immobilized IgG on
the beads was stable and no reduction in the percent binding to hapten was noticed
following 25 days of storage. It was concluded that antibodies could be successfully
immobilized on alginate-chitosan gel  beads.  Such a system can be applied for the
development of immunoaffinity purification and immunoassays.
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Yoshifumi  M.  et  al.,  (2001)  reporded  on preparation of  Alginate  gel  beads  were
prepared which contained weak acid salts  of  chitosan (Alg-CS) and water-soluble
vitamins (e.g. ascorbic acid (AS)) and the behavior of the beads, uptake of bile acids
was  investigated  in  vitro.  The  Alg-CS  beads  rapidly  took  up  bile  acid  and  this
phenomenon was observed for both hydrogel beads and dried beads. About 120 mmol
of taurocholic acid was taken up into Alg-CS (1 g) prepared with orotic acid. Dried
Alg-CS  is  the  granule  which  can  be  made  easily,  and  keephitosan-alginate
multilayered beads fs the ability of CS salt, and all elements can be taken as a food.
Therefore,  Alg-CS  could  serve  as  a  useful  dietary  agent  for  the  prevention  of
hyperlipidemia. 
Ferreira P. et al., (2002) studied that development of a new particulate drug delivery
system using a sodium alginate matrix containing pindolol as a model drug molecule
for intestinal drug prolonged release. Calcium alginate beads are known to be unable
to control the release of most insoluble drugs. Pindolol-loaded alginate–gelatine beads
have  been  developed  using  a  solvent-free  technique  that  involves  a  cross-linking
reaction. Modifications in matrix structure and physicochemical behaviour caused by
the cross-linking reaction were assessed during particle formation and drug release.
Several parameters, such as matrix gelling rate, encapsulation efficiency, drug release
profile and matrix erosion rate, were investigated. Physicochemical characterisation
indicates the formation of a new alginate–gelatine matrix and shows that pindolol
does  not  interfere  with  the  matrix  formation  process.  Matrix  swelling of  calcium
alginate  beads  induced  by  phosphate  buffer  ends  up  in  erosion  and  destruction.
However, for cross-linked beads swelling does not lead to complete erosion, which
may be the main cause of pindolol  retention within the matrix.  The modifications
introduced  in  the initial  calcium alginate  formulation by means  of  an  appropriate
method such  as  the  use  of  a  cross-linking  agent  successfully changed  the  matrix
performance, allowing the controlled release of pindolol. 
Liuxing et al., (2003) studied that the Colon-specific drug delivery systems (CDDSs)
can be used to improve the bioavailability of protein and peptide drugs through the
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oral route. A novel formulation for oral administration using coated calcium alginate
gel  beads-entrapped  liposome and  bee  venom peptide  as  a  model  drug  has  been
investigated  for  colon-specific  drug  delivery  in  vitro.  Drug  release  studies  under
conditions  mimicking  stomach  to  colon  transit  have  shown  that  the  drug  was
protected  from being released  completely in  the physiological  environment  of  the
stomach and small intestine. The release rate of bee venom from the coated calcium
alginate gel beads-entrapped liposome was dependent on the concentration of calcium
and sodium alginate, the amount of bee venom in the liposome, as well as the coating.
Furthermore, a human g-scintigraphy technique was used in vivo to determine drug
delivery more precisely. The colonic arrival time of the tablets was found to be 4–5 h.
The results clearly demonstrated that the coated calcium alginate gel beads-entrapped
liposome is a potential system for colon-specific drug delivery.
 
Wang S.  et  al.,  (2004) prepared poly-l-arginine microcbeads due to  its  nutritional
function and pharmacological efficacy. A high-voltage electrostatic droplet generator
was  used  to  make  uniform  microcapsules.  The  results  show  that  the  membrane
strength and permeating property are both remarkably affected with the changes of
sodium alginate concentration. With the sodium alginate concentration increasing, gel
beads sizes increase from 233µm to 350µm, release ratio is also higher at the same
time, but the membrane strength decreases. 
Patricio J. et al., (2004) developed a new method of  uptake of trivalent chromium by
protonated dry alginate beads from aqueous solutions was investigated at 25 jC in
batch-type  experiments.  The  differences  between  the  mechanisms  associated  with
formation of alginate beads and with metal uptake were demonstrated. Uptake was
coupled with a release of protons; this ion exchange was found to be the mechanism
of the uptake. The uptake was strongly dependent on the Cr-bearing solution pH up to
a value of around 4.5. Uptake reaches a value as high as 112 mg of chromium per g of
alginate beads (dry wt.) at pH 4.5; this uptake is higher than that reported for several
biosorbents. The experimental data fitted the Langmuir adsorption model; however,
the maximum uptake computed from it was 32% lower than the value measured. SEM
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analysis of the cross section of beads after uptake experiments showed no evidence of
precipitation of chromium within the alginate beads at the pH ranges tested. A residual
concentration around 0.3 mg/L of chromium, which allows safe discharge of solutions
having Cr(III),  was reached  when alginate  beads  were  challenged with a  solution
initially having as low as 10 mg/L of the metal. EPMA-EDX analysis of Cr-loaded
beads showed a uniform distribution of chromic species throughout the structure of
alginate beads, regardless of the solution pH. 
 
Anal A.  et al.,  (2004)  prepared chitosan-alginate multilayered beads for ampicillin
and the The aim of this study is to develop multilayer beads with improved properties
for controlled delivery of the antibiotic ampicillin. Ionotropic gelation was applied to
prepare single and multilayer beads using various combinations of chitosan and Ca2+
as cationic components and alginate and polyphosphate as anions. Beads prepared
with higher concentrations of chitosan entrapped more ampicillin. During incubation
in simulated gastric fluid, the beads swelled and started to float but did not show any
sign of erosion. Single layer chitosan–alginate beads released 70% of the drug within
4  h.  Multilayer  beads  released  only 20–30% in  the  same  period  of  time.  During
subsequent incubation in simulated intestinal fluid, both single and multilayer beads
continued to release drug. At least part of this release is due to disintegration of the
beads.  The  rate  of  release  both  in  gastric  and  intestinal  fluid  and  the  kinetics  of
disintegration  in  intestinal  fluid  can  be  controlled  by  changing  the  chitosan
concentration in the coagulation fluid. The release of the drug can also be controlled
by the degree of  cross-linking using polyphosphate.  Cross-linked multilayer  beads
were  prepared  that  released  only  40%  of  the  entrapped  drug  during  24  h.  It  is
concluded that chitosan–alginate multilayer beads, cross-linked with polyphosphate
offer an opportunity for controlled gastrointestinal passage of compounds with low
molecular weight like ampicillin.
 
Willem F. et al., (2005) designed a Chitosan–alginate multilayer beads for controlled
release  of  ampicillin, to  develop  multilayer  beads  with  improved  properties  for
controlled delivery of  the antibiotic  ampicillin.  Ionotropic gelation was applied to
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prepare single and multilayer beads using various combinations of chitosan and Ca2+
as cationic components and alginate and polyphosphate as anions.  Beads prepared
with higher concentrations of chitosan entrapped more ampicillin. During incubation
in simulated gastric fluid, the beads swelled and started to float but did not show any
sign of erosion. Single layer chitosan–alginate beads released 70% of the drug within
4  h.  Multilayer  beads  released  only 20–30% in  the  same  period  of  time.  During
subsequent incubation in simulated intestinal fluid, both single and multilayer beads
continued to release drug. At least part of this release is due to disintegration of the
beads.  The  rate  of  release  both  in  gastric  and  intestinal  fluid  and  the  kinetics  of
disintegration  in  intestinal  fluid  can  be  controlled  by  changing  the  chitosan
concentration in the coagulation fluid. The release of the drug can also be controlled
by the degree of  cross-linking using polyphosphate.  Cross-linked multilayer  beads
were  prepared  that  released  only  40%  of  the  entrapped  drug  during  24  h.  It  is
concluded that chitosan–alginate multilayer beads, cross-linked with polyphosphate
offer an opportunity for controlled gastrointestinal passage of compounds with low
molecular weight like ampicillin. In this work, an anti-drug antibody was immobilized
on  alginate-chitosan  beads  using  a  glutaraldehyde  covalent  binding  method.  The
different  parameters  affecting  the  immobilization  process,  the  antibody
immunoreactivity  and  performance  were  investigated.  This  conjugation  method
retains  the  immunoreactivity  of  the  antibody,  which  makes  it  suitable  for  further
immunological reactions. 
Vani  M.  et  al.,  (2006)  designed a  gastro  retentive  floating  beads  of  ranitidine
hydrochloride  were  formulated  to  increase  the  residence  time  in  stomach  and  to
sustain  the  release  behavior  of  the  drug  and  increase  drug  bioavailability  .The
ranitidine hydrochloride floating beads were done by extrusion congealing method,
because the major site of absorption of ranitidine hydrochloride is being the stomach,
to  extend  the  period  of  residence  of  the  drug  in  the  stomach to  leave  maximum
absorption.  Nine  formulations  of  ranitidine  hydrochloride  floating  beads  were
formulated  by  extrusion  congealing  technique  using  different  percentage  of  gas
forming agent and polymers, HPMC and sodium alginate. The content of drug release
was done by UV spectrophotometer at 322 nm. The particle size analysis was done by
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vernier calliper which was found to be in the range of 0.1-0.3. In vitro drug release of
ranitidine hydrochloride, for F2 (3%w/w HPMC) and F6 (4%w/w HPMC) were found
to be 80.12% and 81.10% respectively, at the end of 480 m in simulated gastric fluid
(pH 1.2). The percentage drug entrapment and drug content of the formulated beads
were found to be satisfactory by this method. From the study it was concluded that the
gastro retentive drug delivery system designed as  floating beads could be suitable
drug delivery system for Ranitidine HCl. Further the  in vivo  absorption studies will
confirm the suitability of the formulated dosage form.
George P.  et al., (2006) prepared a method to investigate the swelling behavior and
the  in  vitro  release  of  the  antihypertensive  drug  verapamil  hydrochloride  from
calcium alginate and chitosan treated calcium alginate beads. Calcium–alginate beads,
chitosan-coated alginate beads and alginate–chitosan mixed beads were synthesized
and their morphology was investigated by scanning electron microscopy. The swelling
ability of the beads in different media was found to be dependent on the presence of
the polyelectrolyte complex between alginate and chitosan, the pH of the aqueous
media  and  the  initial  physical  state  of  the  beads.  The  results  revealed  that  the
encapsulation of verapamil in both calcium–alginate and calcium alginate–chitosan
mixed  beads  exceeded  80%.  Considering  the  in  vitro  stability  of  verapamil
encapsulating  beads,  70%  of  the  drug  released  from  wet  and  dry  plain  calcium
alginate beads within 1 and 3 h, respectively. The presence of chitosan was found to
retard significantly the release from wet beads. However, in the case of dry beads the
presence  of  chitosan  had  no  significant  effect  on  the  initial  release  stage  and
significantly increased the release on the later stage. The results were analyzed by
using a semi-empirical equation and it was found that the drug release mechanisms
were either “anomalous transport” or “case-II transport”
Piyakulawat P. et al., (2006) studied that the hydrogel beads based on chitosan (CS)
and carrageenan (CR) have been used as a controlled release device to deliver sodium
diclofenac  (DFNa)  in  the  simulated  gastrointestinal  condition.  Various  factors
potentially influencing the drug release (ie, CS/CR proportion, DFNa content, types
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and amount of cross-linking agents) were also investigated. The optimal formulation
was obtained with CS/CR proportion of 2/1 and 5%(wt/vol) DFNa. The controlled
release of the drug from this formulation was superior to other formulations and was
able to maintain the release for ~8 hours. Upon cross-linking with glutaric acid and
glutaraldehyde,  the resulting beads were found to be more efficient  for prolonged
drug release than their  non-cross-linking counterparts.  The  bead  cross-linked with
glutaraldehyde  was  able  to  control  the  release  of  the  drug  over  24  hours.  The
difference in the drug release behaviour can be attributed to the differences in ionic
interaction between the oppositely charged ions and to the concentrations of the drug
within the beads, which depends on the compositions of the formulation and the pH of
the dissolution medium. The release of drug was controlled by the mechanism of the
dissolution of DFNa in the dissolution medium and the diffusion of DFNa through the
hydrogel beads 
Shishu S.  et  al.,  (2006) developed  a  multiple-unit-type oral  floating dosage  form
(FDF)  of  5-  fluorouracil  (5-FU) to  prolong gastric  residence time,  target  stomach
cancer,  and  increase  drug  bioavailability.  The  floating  bead  formulations  were
prepared  by  dispersing  5-FU  together  with  calcium  carbonate  into  a  mixture  of
sodium alginate and hydroxypropyl methylcellulose solution and then dripping the
dispersion into an acidified solution of calcium chloride. Calcium alginate beads were
formed, as alginate undergoes ionotropic gelation by calcium ions and carbon dioxide
develops from the reaction of carbonate salts with acid. The evolving gas permeated
through the alginate matrix, leaving gas bubbles or pores, which provided the beads
buoyancy.  The  prepared  beads  were  evaluated  for  percent  drug  loading,  drug
entrapment efficiency, image, surface topography, buoyancy, and in vitro release. The
formulations  were  optimized  for  different  weight  ratios  of  gas-forming  agent  and
sodium  alginate.  The  beads  containing  higher  amounts  of  calcium  carbonate
demonstrated instantaneous, complete, and excellent floating ability over a period of
24 hours. The optimized formulation was subjected to in vivo antitumor studies to
check the therapeutic efficacy of the floating dosage forms containing 5-FU against
benzo(a)pyrene-induced stomach tumors in albino female mice (Balb/C strain). The
multiple-bead FDF was found to reduce the tumor incidence in mice by 74%, while
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the conventional  tablet  dosage  form reduced this  incidence  by only 25%. Results
indicate that FDF performed significantly better than the simple tablet dosage form. 
Gupta E. et al., (2007) prepared a multiple-unit-type oral floating dosage form (FDF)
of  5-  fluorouracil  (5-FU)  was  developed  to  prolong gastric  residence  time,  target
stomach cancer,  and  increase  drug  bioavailability.  The  floating  bead  formulations
were prepared by dispersing 5-FU together with calcium carbonate into a mixture of
sodium alginate and hydroxypropyl methylcellulose solution and then dripping the
dispersion into an acidified solution of calcium chloride. Calcium alginate beads were
formed, as alginate undergoes ionotropic gelation by calcium ions and carbon dioxide
develops from the reaction of carbonate salts with acid. The evolving gas permeated
through the alginate matrix, leaving gas bubbles or pores, which provided the beads
buoyancy.  The  prepared  beads  were  evaluated  for  percent  drug  loading,  drug
entrapment efficiency, image, surface topography, buoyancy, and in vitro release. The
formulations  were  optimized  for  different  weight  ratios  of  gas-forming  agent  and
sodium  alginate.  The  beads  containing  higher  amounts  of  calcium  carbonate
demonstrated instantaneous, complete, and excellent floating ability over a period of
24 hours. The optimized formulation was subjected to in vivo antitumor studies to
check the therapeutic efficacy of the floating dosage forms containing 5-FU against
benzo(a)pyrene-induced stomach tumors in albino female mice (Balb/C strain). The
multiple-bead FDF was found to reduce the tumor incidence in mice by 74%, while
the conventional  tablet  dosage  form reduced this  incidence  by only 25%. Results
indicate that FDF performed significantly better than the simple tablet dosage form. 
 
Khazaeli  P.  et  al.,  (2008)  designed  formulation  of  gel  beads  of  Ibuprofen  by
ionotropic gelation method. Formulation of ibuprofen in beads could reduce its gastric
ulcerogenicity.  Alginate  has  a  unique  gel-forming  property  in  the  presence  of
multivalent cations, in an aqueous medium. Hence, in this study the formation of Ca-
alginate ibuprofen beads, through ionotropic gelation has been investigated.For this
purpose, different cross- linking agents including: Ca2+, Ba2+, Mn2+, Co2+, Sn2+
and Pb2+, were used for bead preparation. Next, characterization of the beads, size
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distribution, encapsulation efficiency of ibuprofen within the beads, the bead swelling
and the drug release kinetic were investigated.Results showed that  only Ca ion is
suitable for the formation of ibuprofen beads. A good swelling profile for beads in
phosphate buffer (pH=7.4) and the lack of swelling in hydrochloric acid (pH= 1.2),
show the suitable nature of the beads. In addition, formulation of Na-alginate (2%)
and Ca-chloride (2%) beads resulted in an encapsulation efficacy of around 90%. The
drug release studies showed a rapid and complete ibuprofen release from the beads,
especially those prepared from Na-alginate (2%) and Ca-chloride (2%), in phosphate
buffer medium. However, no detectable drug release was observed within the acidic
medium. In conclusion, ibuprofen is capable of being be microencapsulated as a bead
formulation, with suitable properties and release profile. 
Mishra S. et al., (2008) Formulated oil entrapped gastro retentive floating gel beads
of  loratadine.  A  gastro  retentive  controlled  release  system  of  loratadine  was
formulated to increase the residence time in  stomach and to  modulate the release
behaviour of the drug. Oil entrapped floating microbeads prepared by the emulsion
gelation method were optimized by 23 factorial design and a polymer ratio of 2.5:1.5
(pectin/sodium alginate) by mass, 15% (m/V) of oil (mineral oil or castor oil) and 0.45
mol  L–1 calcium chloride solution as  the optimized processing conditions  for  the
desired  buoyancy  and physical  stability.  In  vitro  drug  release  in  the  fed  state
conditions demonstrated sustained release of loratadine for 8 h, which best fitted the
Peppas model with n < 0.45. The ethyl cellulose coating on microbeads optimized by
factorial design resulted in a controlled release formulation of loratadine that provided
zero-order release for 8 h.
Venkatesh D. et al., (2008) developed a method to treat cough by preparing alginate
beads of ambroxol Hydrochloride. Ambroxol, a mucolytic agent has been used for
decades as a secretion releasing expectorant in the treatment of variety of respiratory
disorders. This drug has a shorter half life 4 h4 that requires frequent daily dosing and
chronic  respiratory  diseases  necessitates  its  formulation  into  a  sustained  release
dosage form. Once or twice daily administration of controlled release preparations is
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recommended  and  improves  patient  compliance. The  major  drawback  of  orally
administered  drug  like  ambroxol  as  mucolytic  agent  in  a  variety  of  respiratory
disorders has a shorter biological half-life. To overcome these drawbacks, an attempt
has been made to develop a sustained release dosage form of ambroxol embedded
alginate  microbeads  prepared  by  ionotropic  gelation  technique.  The  beads  were
characterized for its particle size, drug content and in vitro release studies. The results
revealed that the surface adhering drug was found to release immediately and a steady
state of release was obtained up to 12 h from all the batches. The results indicated
there  was  an  inverse  relationship  between  the  concentration  of  alginate  and  drug
release. The drug release was found to follow non-fickian diffusion obeying first order
kinetics.These microbeads were characterized for its particle size, drug content and in
vitro  drug release studies. An attempt was also made to understand the mechanism
involved in the release kinetics of alginate microbeads. 
 
Gattani S.  et al., (2009) designed Floating-Muco adhesive Beads of Clarithromycin
for the Treatment of  Helicobacter pylori  Infection.An excellent concept of floating
system suffers from a disadvantage that it is effective only when the fluid level in
stomach is sufficiently high; however, as the stomach empties and the tablet is at the
pylorus, the buoyancy of the dosage form may be impeded. This serious limitation
can be overcome by the use of bio-adhesive polymers to enable it to adhere to the
mucous lining of stomach wall. Floating and bio-adhesive drug delivery systems offer
the  advantages  of  increased  contact  time  with  stomach  mucosa,  more  effective
absorption  and  bioavailability  of  drugs  with  absorption  windows  near  proximal
intestine and stomach, and low dosing frequencies .Our main aim of the present study
was  to  develop  alginate/hydroxypropyl  methylcellulose  (HPMC)  based  floating-
mucoadhesive beads of clarithromycin to provide prolonged contact time of antibiotic
to treat stomach ulcer. Floating-mucoadhesive beads were prepared and characterized
for  in vitro  performance followed by investigation of  ex vivo  study in albino-wistar
rats. Beads were prepared by ionic gelation technique where calcium chloride used as
gelating agent and incorporated liquid paraffin for floating of the beads.  Prepared
beads  were evaluated  extensively for  particle  size,  drug entrapment;  swelling and
surface  morphology  by  using  scanning  electron  microscopy.  X-ray  radioimaging
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study in rabbits, in vitro mucoadhesion using rat stomach mucosal membrane and in
vitro  drug release studies were carried out.  Ex vivo  performance of alginate-HPMC
beads were studied using albino rats in comparison to simple alginate-calcium beads.
Alginate-HPMC beads may be suitable floating-muco-adhesive drug delivery system
for delivering clarithromycin to treat stomach ulcers Stomach-specific antibiotic drug
delivery would be highly beneficial in the treatment of  H. pylori  infection in peptic
ulcer  disease.9)  Clarithromycin  is  having  good  stability  in  a  gastric  pH.10)  The
present work describes incorporation of an active component known to be effective
against  H. pylori,  clarithromycin, into alginate (Alg)-Ca and Alg-HPMC beads and
reports the release of drug from the beads in an acidic environment and also applies
the new approach of mucoadhesive and floating for synergistic effect.
Bindu  B.  et  al.,  (2009)  prepared  an  anti-depression  therapy  by  formulating
venlafaxine hcl enclosed in alginate microbeads prepared by iontophoretic gellation
method.  Venlafaxine  hydrochloride  (VEN)  is  a  representative  of  a  new  class  of
antidepressants. VEN, commercially known as “Effexor” is a representative of a new
class of antidepressants with a dose of 25mg-45mg. It acts by inhibiting selectively
the uptake of serotonin and noradrenaline but shows no affinity for neurotransmitter
receptors. Higher solubility in water results in burst effect with sudden peak levels of
drug  in  blood.  The  half  lives  of  VEN  and  its  active  metabolite  O-desmethyl
venlafaxine are  5hr  and 11hr respectively.  The micro beads  were prepared by the
ionotropic gelation of  sodium alginate  in  calcium chloride  solution.  The prepared
micro beads were evaluated mainly for the sustain release of the drug apart from the
other tests like, % drug encapsulation, particle size and drug polymer compatibility by
the  FTIR  studies.  The  method  had  resulted  in  good  encapsulation  efficiency and
micron sized alginate spheres.  The drug release was found to be sustained for  16
hours.  Patients  who  experience  intolerable  nausea  with  an  immediate-release
formulation despite seeing improvement in their depressive symptoms might benefit
from taking a controlled-release formulation of the same antidepressant or switching
to another of the newer antidepressants. To reduce the adverse effects and to have the
controlled release of the drug we have prepared the alginate micro beads of the drug.  
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Jaiswal D. et al., (2009) studied formulation and evaluation of oil entrapped floating
alginate beads of ranitidine hydrochloride . They develop a multi-unit gastro retentive
sustained release dosage form of a water soluble drug, Ranitidine hydrochloride, from
a completely aqueous environment avoiding the use of any organic solvent, which
could cure peptic ulcer more efficiently by releasing the drug especially in stomach
and also for a prolonged duration of time. A new emulsion gelation technique was
used to prepare emulsion gel beads using sodium alginate as the polymer. The gel
beads containing oil was prepared by gently mixing or homogenizing oil and water
phase containing sodium alginate which was then extruded in to calcium chloride
solution. The effects of factors like concentration of oil, curing time, drug: polymer
ratio, alginate: pectin ratio and curing agent on drug entrapment efficiency, floating
lag time, morphology and drug release were studied. Minimizing the curing time of
beads  leaded  to  enhanced  drug  entrapment  efficiency.  It  was  found  that  sodium
alginate was not sufficient  to  sustain the drug release at  gastric pH.  Instead of it,
appropriate combination of alginate and pectin could provide the sustain release of
drug.  The results  show that  these  beads can  entrap  even  a water  soluble drug as
Ranitidine hydrochloride in sufficient amount and also can successfully deliver the
drug in stomach for a prolong duration of time without using any organic solvent and
any time consuming step in the preparation.
 
Shaji  S.  et  al.,  (2009) prepared  multi  particulate  gastro  retentive  dosage  form of
famotidine  for  better  control  of  gastric  acidity. The  concept  of  multiunit  gastro
retentive beads can be utilized to provide a more reliable and long lasting release of
drug in the stomach for local and systemic action. The floating gel beads beneficially
alter the absorption of drug, thereby enhancing bioavailability. Famotidine, being a
poorly bioavailable drug due to reasons unrelated to hepatic metabolism, is ideally
suited to be delivered through a controlled release floating multiunit dosage form for
slow release  in  the  stomach and  subsequent  complete  absorption  in  the  intestine.
Worldwide accepted clinical therapy of acid peptic disease is based on histamine H2
receptor antagonists. The four H2 receptor antagonists currently available on market
are Cimetidine, Ranitidine, Famotidine, and Nizatidine. Out of these drugs famotidine
is  the  most  widely  used  and  accepted  drug  for  the  treatment  of  peptic  ulcer.
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Famotidine is  having fewer  side effects  than  the  other  congeners  and it  does  not
appear  to  exhibit  anti  androgenic  activity or  affect  the  hepatic  clearance  of  other
drugs. Famotidine is having low bioavailability (40%), so there is a continued effort
to  improve  the  pharmaceutical  formulation  of  famotidine  in  order  to  achieve  an
optimized therapy. 
 
Salunke K.  et al.,  (2010) prepared a floating microcarriers of an antidiabetic drug
Metformin  hydrochloride  is  an  Antihyperglycemic  agent  widely  used  in  the
management of NIDDM. Absolute oral bioavailability of Metformin hydrochloride is
50-60% due to its site-specific absorption limitations. It is safe drug and it has a half-
life of 2 hrs.  It  is  not absorbed completely and gives low bioavailability problem.
Almost 80-100% of the drug is excreted unchanged. The total daily requirement of
Metformin hydrochloride is 1.5-3g/day. Henceforth, there being high incidence of GI
side  effects  and  toxicity  .  Therefore,  there  are  continued  efforts  to  improve  the
pharmaceutical  formulation  of  Metformin  hydrochloride  in  order  to  achieve  an
optimal therapy. Bioavailability of the drug has been found to be reduced further with
sustained release dosage forms, probably due to the fact that passage of the sustained
release single unit dosage forms from absorption region of the drug is faster than its
release and most of the drug released at the colon where Metformin hydrochloride is
poorly absorbed . Floating microbeads  were prepared from a sodium alginate solution
containing CaCO3 and NaHCO3 as gas-forming agents. The solution was dropped to
5% CaCl2 solution containing 10% acetic acid for CO2 gas and gel formation. The
effects  of  gas-forming  agents  on  microcarrier  size  and  floating  ability  were
investigated. As concentration of gas-forming agents increased, the size and floating
ability also increased.  Microcarrier’s  surface and cross-sectional  morphology were
examined  with  Scanning  Electron  Microscopy.  NaHCO3  significantly  increased
porosity  and  pore  diameter  than  CaCO3.  Incorporation  of  CaCO3  into  alginate
solution resulted in smoother  microcarriers than those produced with NaHCO3 as
well as it showed high drug entrapment. Microcarriers incorporating CaCO3 exhibited
significantly increased gel  strength over  control  and NaHCO3-containing samples.
Release rate  of Metformin hydrochloride increased proportionally with addition of
NaHCO3. However, increasing weight ratios of CaCO3 did not appreciably accelerate
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drug release. The results of these studies indicate that CaCO3 is superior to NaHCO3
as  an  effervescent  agent  in  alginate  micro  carrier’s  preparations.  The  enhanced
buoyancy and sustained release properties of CaCO3-containing beads make them an
excellent candidate for floating drug dosage systems 
Yellanki S. etr al.,  (2010) prepared a multiple unit type oral floating dosage form
(FDF) of Riboflavin was developed to prolong gastric residence time, and increase
drug  bioavailability.  The  floating  bead  formulations  were  prepared  by  dispersing
Riboflavin together  with calcium carbonate into a mixture of sodium alginate and
hydroxypropyl  methylcellulose  solution  and  then  dripping  the  dispersion  into  an
acidified solution of 1% (w/v) calcium chloride. The formulations were optimized for
different  weight  ratios  of  gas  forming  agent  and  sodium  alginate.  Prepared
microbeads were evaluated for Particle size, Scanning electron microscopy, In‐Vitro
buoyancy study,  Drug entrapment  efficiency and In  Vitro  drug release.  The beads
containing  higher  amounts  of  calcium  carbonate  demonstrated  instantaneous,
complete, and excellent floating ability. All the formulations remained buoyant and
controlled release for  up to 10 hrs.  The mechanism of  drug release was found to
follow  Higuchi  matrix  order  release.  Results  indicate  that  FDF  performed
significantly  better  than  the  simple  tablet  dosage  form  .In  context  of  the  above
principles, a strong need was recognized for the development of floating dosage form
to deliver Riboflavin (model drug) in stomach to increase the efficiency of the drug,
providing sustained release. 
Tripathi G. et al., (2010) designed a buoyant beads of clarithromycin .They develop
a consistent formulation of Cl that enjoys all the advantages of a floating single unit
dosage form but at  the same time being devoided of  disadvantages of single unit
dosage forms, like sticking or being obstructed in the gastrointestinal tract.  Buoyant
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beads  of  gellan  was  developed  by  inotropic  gelation  technique  using  calcium
carbonate as gas forming agent and the drug polymer dispersion was emulsified with
mineral oil. The oil was entrapped and blended with hydroxypropyl methyl cellulose
or  carbopol  934.  The  developed  beads  were  evaluated  in  terms  of  diameter,  %
floating,  encapsulation  efficiency,  In  vitro  drug  release,  In  vivo  gastric  residence
efficacy and clarithromycine concentration in the mucosa of the experimental animal
model.  The  scanning  electron  microscope  photograph  indicated  that  the  prepared
beads  were  spherical  in  shape  and  buoyancy,  encapsulation  efficiency  and  drug
content  obtained  from  all  batches  were  satisfactory.  Particle  size  and  percentage
buoyancy  of  the  gel  beads  increased  by  raising  the  concentration  of  calcium
carbonate. 
Goudanavar P.  et al., (2010) prepared microbeads for Diclofenac sodium prepared
by ionotropic gelation technique using Sodium alginate alone and combination with
Hydroxypropyl  methyl  cellulose,  Chitosan,  Pectin  as  release  rate  modifiers,  and
investigated  for  flow behavior,  particle  size,  swelling properties,  surface  study by
SEM,  and  in  vitro  drug  release  potential.  While  increase  in  the  concentration  of
sodium alginate and other polymer dispersions increased sphericity, size distribution,
mean particle size.  Drug entrapment efficiency approached nearly 95%. Increasing
calcium chloride concentration decreases the mean diameter of the microbeads, no
appreciable change in morphology, and drug release behaviors. In vitro drug release
was dependent on the pH of the medium and concentration of polymer dispersions.
Among the nine formulation batches F5, F7 and F9 were found to show optimum
sustained effect. The mechanism of drug release from the microbeads was found to be
followed super case-II transport.
Manjanna K.  et  al.,  (2010)  Prepared  Calcium  alginate  cross-linked  polymeric
microbeads of aceclofenac for oral sustained drug delivery in arthritis  aceclofenac, a
novel  NSAID  used  in  the  treatment  of  rheumatoid  arthritis,  frequency  of
administration may cause certain GI-adverse effects.He  develop a microparticulate
oral sustained release dosage form, to reduce dosing frequency, to eliminate the dose
related adverse effects and to ultimately improve compliance in the pharmacotherapy
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of  arthritis.  The  microbeads  were  prepared  by  an  ionotropic  external  gelation
technique, by using sodium alginate as the hydrophilic carrier and calcium chloride as
the  crosslinking  agent.   The  mean particle  sizes  of  drug-loaded  microbeads  were
found to be in the range 596.45 ± 1.04 to 880.10 ± 0.13 µm. The drug entrapment
efficiency was obtained in the range of 63.24-98.90% (w/v). The release of drug from
the microbeads at pH 1.2 is negligible. Under neutral conditions, the beads will swell
and the drug release  on swelling and the erosion process resulting in an optimum
level of drug released in a sustained manner which exhibits zero-order kinetics. 
Kawadkar J. et al., (2010) prepared Colonic drug delivery (CDD), Zn-pectinate gel
(ZPG) microbeads of  masalazine is  intended for the local  treatment of  ulcerative
colitis, inflammatory bowel diseases and can potentially be used for colon cancer or
the systemic administration of drugs that are adversely affected by the upper gastro-
intestinal  (GI)  tract  .  CDD  have  advantages  of  minimum  systemic  absorption,
administration of lower drug doses, high concentrations of drug in the distal small
intestine  and  the  colon  without  systemic  exposure  and  toxicity.  There  has  been
considerable  investigation  for  the design  of  CDD systems  and  targeting has  been
achieved by different methods. Delivery systems controlling release of drug only in
the colon has been reported. MZ (t1/2: 0.6 to 1.4 hrs) is rapidly absorbed from the
small  intestine  and  there  is  a  little  localization  in  the  colon  relative  to  the  small
intestine.  Therefore,  to  increase  its  localization  in  the  colon;  development  of  a
polysaccharide based delivery system is required. The rationale for the development
of  a  polysaccharide  based  delivery system for  colon  is  the  ability  of  the  colonic
microfolra  to  degrade  various  types  of  polysaccharides  that  escape  small  bowel
digestion. Major efforts have been focused should be deleted for pectin derivatives
and use of  calcium and zinc salts  of  pectin  because  binding of  calcium and  zinc
induces  non-covalent  associations  of  carbohydrate  chains  through  “eggbox”
complexes, which are more water resistant, while still enzymatically degradable. In
this study the effects  of different  formulation variables upon the characteristics of
pectinate microbeads prepared by ionotropic gelation technique for colonic delivery
of mesalazine was investigated. 
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Sangeetha  S.  et  al.,  (2010) prepared  Gastroretentive  bead  of  theophylline  by
ionotropic gelation  was  formulated  in  two different  combinations  such  as  sodium
alginate along with guar gum and sodium alginate with hydroxy ethyl cellulose. The
gas  forming  agent’s  calcium  carbonate  was  also  added  in  four  different
concentrations.  The  formulated  beads  were  then  evaluated  for  particle  size,  drug
content, floating properties and invitro dissolution. The invitro release study showed
about 98‐99% of drug release at the end of 8 hrs with good buyoncy effect for the
batch formulated with the combination of sodium alginate and guar gum. The invitro
release mechanism was found to be analomous diffusion with first order kinetics .
Ahmed M. et al., (2010) designed an new oral drug delivery system was developed
utilizing both the concepts of controlled release and mucoadhesiveness, in order to
obtain a unique drug delivery system which could remain in stomach and control the
drug  release  for  longer  period  of  time.Gastro-retentive  beads  of  captopril  were
prepared by orifice ionic gelation method in 1:1 and 9:1 ratio of alginate along with
mucoadhesive  polymers  viz;  hydroxy  propyl  methyl  cellulose,  carbopol  934P,
chitosan  and  cellulose  acetate  phthalate.  The  prepared  beads  were  subjected  for
various evaluation parameters.The percentage drug content was found to be in the
range of 59.4 - 91.9 percent for beads. It was observed that as the alginate proportion
was increased, the average size of beads also increased. Photomicrographs revealed
that the beads were spherical in shape. Alginatechitosan (9:1) beads showed excellent
microencapsulation  efficiency  (89.7  percent).  Alginate-  Carbopol  934P  exhibited
maximum efficiency of mucoadhesion in 0.1 N hydrochloric acid (44 percent for 1:1
and  22  percent  for  9:1)  at  the  end  of  8  hours,  whereas  least  mucoadhesion  was
observed with alginate-Cellulose acetate phthalate beads. The in vitro release studies
were carried out in 0.1 N hydrochloric acid and the release were found to be more
sustained  with  Alginate-chitosan  beads  (9:1)  than  Alginate-Carbopol  934P  (1:1)
beads.  The  alginate-cellulose  acetate  phthalate  beads  showed  the  better  sustained
release as compared to all other alginatepolymer combinations. Regression analysis
showed that the release followed zero order kinetics in 0.1 N hydrochloric acid (pH
1.2). The objectives of the present work was achieved ie, formulation, evaluation and
usefulness  of  sodium  alginate  mucoadhesive  beads  of  captopril  with  different
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mucoadhesive  polymers.  Certainly  these  findings  can  be  applied  for  sustained
delivery of drugs with mucoadhesion. Further these findings help the industry to scale
up the commercial production 
Sakthisaravanan V.  et al., (2010) studied on gastro retentive beads of theophylline
by ionotropic gelation.There are various approaches which have been worked out to
improve the retention of an oral dosage form in the stomach, e.g. floating systems,
swelling and expanding systems, modified‐ shape systems, bioadhesive systems, high
density systems and other delayed gastric emptying device.  Floating drug delivery
systems (FDDS) or hydro dynamically balanced systems (HBS) have a bulk density
lower than gastric fluids and therefore remains floating in the stomach unflattering the
gastric emptying rate for a prolonged period. This leads to an increase in the gastric
retention time and a better control over fluctuations in plasma drug concentration.
Sodium alginate and guar gum (hydrocolloids) were used to prepare beads as sodium
alginate  and  guar  gum  is  naturally  occurring  polymer  widely  used  in  various
formulations and HEC a synthetic polymer.  Hence based on all the discussion we
have planned  to  investigate  the  feasibility of  the  formulations  such  as  to  prepare
gastro retentive beads by ionotropic gelation with the help of sodium alginate with
HEC and also sodium alginate with guar gum as two different formulations, to find
out whether varying the concentrations of calcium carbonate express any substantial
effect on the invitro release and floating ability for the formulated beads.
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Table-2  :  Various  types  of  Gel  Beads  by  using  different  Drugs  and different
Polymer.
Anti inflammatory drug
SI.
No
Types Drug Polymer Significance Reference
1 Gel beads Sodium
diclofenac
Chitosan,
carrageenan
-Crosslinked  beads
with  glutaric  acid
shows  better  result
then non crosslinked.
-Crosslinked  beads
with  glutareldehyde
is best with regard to
effectiveness  for
Pimwipha
et.al.2007
Dept. of Pharmaceutics 43 JKKMMRF College of Pharmacy
Chapter 02                                                                                                    Review of
literature
prolong drug release.
2 Gel beads Ibuprofen Sodium alginate -Calcium chloride  is
best,over
Bacl2,Mncl2,Cocl2 &
Sncl2
Khazaeli
et.al.2008
3 Hydrophilic
polymeric
beads
Sodium
diclofenac
Sodium alginate,
sodium CMC
-Sodium  CMC
shows more  prolong
drug  deliver  than
sodium alginate.
Dhanaraju
et.al.2010
4 Agarose
beads
Aceclo-
fenac
Sodium alginate -Swelling  index  is
increased  and  drug
release  rate  is
decreased  with
increasing  polymer
concentration.
Yesmin
et.al.2008
Dept. of Pharmaceutics 44 JKKMMRF College of Pharmacy
Chapter 02                                                                                                    Review of
literature
SI.
No
Types Drug Polymer Significance Reference
5 Microbeads Ibuprofen Sodium alginate -Sweet  potato  flour
is a potentially useful
natural  materials  for
making  controlled
release  drug  loaded
microbead  by
ionotropic  gelation
method.
Jha
et.al.2010
6 Microbeads Diclofenac Chitosan,
HPMC
-Formulation  with
1%HPMC&1%chito-
san  shows  more
sustained  release
than other.
Goudanavar
et.al.2010
7 Gel beads Ketoprofen Sodium alginate -As  HPMC
concentration
increase,sustained
release  also
increased.
Giunchedi
et. al. 2004
8 Gel beads Flurbi-
profen
Cetylalcohol,
ethyl alcohol
-Beads  shows  more
sustained  release
upto 12 hrs.
-Inherent  strength of
melt solidified bonds
of  drug  helped  to
reduce the amount of
excipient  required to
retard release.
Maheshwari
et.al.2003
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No
Types Drug Polymer Significance Reference
9 Calcium
pactinate
beads
Aceclo-
fenac
Low  methoxy
pectin,
sodium alginate
-As  sodium  bi-
carbonate
concentration
increased,floating
ability  of  beads
increased.-
Somani
et.al.2010
Anti ulcer drug
10 Floating
beads
Ranitidine Sodium alginate %EE  of  beads
prepared  with  two
type  of
polymer(sod.alginate
&pectine)  is  more
than  one  type  of
polymer  sodium
alginate.
-As  Polymer
concentration
increased,swelling
ratio decreased.
-Oil  act  as  a  water
barrier
Jaiswal
et.al.2009
Anti biotics (beta lactamase)
11 Multi
layered
beads
Ampicillin Sodium alginate -Chitosan  beads
more  efficient  than
alginate beads.
-Multilayered  beads
showed  more  delay
in release of drug in
chitosan-alginate
beads
Anal
et.al.2005
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12 Polymer
network
beads
Ofo-floxacin Chitosan,
Sodium alginate
-Highest  dissolution
rate is observed with
chitosan and sodium
alginate  and  lowest
with chitosan.
Kulkarni
et.al.2010
13 Floating
muco-
adhesive
beads
Clarithro
mycine
HPMC,
Sodium alginate
-Alg.-calcium  beads
shows  rapid  release
of drug within 3 to 5
hrs.
Gattani  
et. al.2010
Respirtory system
14 GIT
beads
Theophylline Guar gum,
Sodium alginate,
Hydroxyl  ethyl
cellulose
-Theophylline
release is faster from
hydroxyl  ethyl
cellulose  beads  with
alginate,  when
compared  with  guar
gum-alginate.
-On increasing conc,
of  CaCO3,rate  of
release increased.
Sangeetha
et.al .2010
15 PH
depen-
dent
beads
Theophylline Chitosan,
 sodium alginate
-Longer  of  cross
linking  time,lower
the size of beads.
Khan
et.al.2010 
16 Alginate
beads
Ambroxol Sodium alginate -It  suggest  that  gel
strength  of  alginate
plays an IMP role in
controlling  drug
release
-Release rate of drug
from  beads
decreased.
Venkatesh
et.al.2008
17 Micro-
beads
Theophylline Chitosan,
Sodium alginate
-As  conc.  Of
polymer  increased,
size  of  beads  also
increased.
-Lower cross linking
time, lower the size
Diameter  of  gel
beads.
Sridhar
et.al.2010
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18 Floating
alginate
beads
Riboflavin Sodium alginate,
HPMC
-Increased  CaCO3
conc.,prolongs  the
release of drug from
beadsWithout
CaCO3,  formulation
shows  better  release
than  gas  forming
agent.
Yellanki
et.al.2010
19 Alginate
beads
Water
soluble
vitamin.
(bile acid)
Sodium alginate,
Chitosan
-Alginate-Chitosan
could  potentially  be
useful  for  uptake  of
bile salts.
-  Alginate-Chitosan
suitable  for  daily
intake  Orally
administered,
Muratta
et.al.2001
Proteins
20 Chitosan-
alginate
beads
Lisinopril Sodium alginate,
Chitosan
-IgG  antibodies  has
been  covalently
bound  to  Alginate-
Chitosan beads using
gluteraldehyde.
-The  successful
immobilization of Ab
on Alginate-Chitosan
beads  provides  a
good  system  for
immunoaffinity
purification&develop
-.ment of solid phase
immunoassay
Albar-
ghouthi
et.al.2000
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SI.
No
Types Drug Polymer Significance Reference
21 Gellen
beads
Hydrochlor
thiazide
Gellen gum -Gellen
hydrochlorthiazide
beads system can be
employed  in  anti-
hypertensive
treatment.
-Also  in  patients
requiring  diuresis
where  sustain  action
of drug require.
-Hydrochlorthiazide
release  from  beads
followed  sustain
action.
Emeje
et.al.2009
Anti ulcer drug
22 Floating
beads
5-
fluorouracil
Sodium alginate,
HPMC
Results  shows  that
release of drug from
beads  prolongs  upto
24 hrs.
-Delay  in  %drug
release  with
increased  In  CaCO3
concentration
Gupta
et.al.2007
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SI.
No
Types Drug Polymer Significance Reference
23 Muco
adhesive
miocro
beads
Timolol Sodium alginate -Natural
mucoadhesive
system  along  with
sodium  alginate
shows sustained  and
modulated  in
cointrolling  release
of  timolol  from
microbeads.
-Dissolution  follows
zero,first and higuchi
model
Sharma
et.al.2009
Anti-histamine drug
24 GIT
floating
beads
Loratadine Low  methoxy
pectinate,
Ethyl cellulose
-Release rate follows
zero order.
-GIT  formulation  of
drug  having
excellence  buoyant
ability  and  sustain
drug  release  pattern
could  possibly
advantageous  in
turns  of  increased
bioavailability  of
drug.
-GIT  beads  with
mineral  oils  shows
smaller  diameter
than castor oils.
Mishra
et.al 2008
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SI.
No
Types Drug Polymer Significance Reference
25 Micro
cannel
bead
Iso-octane
N-haxene
Gelatin -Gelatin  microbeads
with  narrow  size
distribution by using
channel
emulsification,  a
novel technology for
preparing  W/O  or
O/W emulsion.
-Dried  gelatin
microbeads could be
resuspended  well  in
iso-octane 
Lwamoto
et.al.2001 
Micro-orgenism
26 Calcium
Alginate
beads
Lacto
coccus lacti
Alginate -Presence of  CaCO3
helps  in  to  maintain
firmness  of  alginate
beads  despite
increased  production
of lactic acid.
-Highest  yield  were
obtained in milk and
gold,complet
sustained  with
CaCO3.
Morin
et.al.1991
27 Gel beads Tamarind
gum
Sodium alginate -Intresting  for  bio-
medical application.
-Gel  beads  are
promising  as  a
potentially  good
support  to  be
employed  in
immobilization  cell
carrier  terminology
and  fermentation
industry  with  good
economical
feasibility  and  good
quality.
Zhang
et.al.2008
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AIM AND PLAN OF WORK
Oral controlled release drug delivery is a drug delivery system that provides
the continuous oral delivery of drugs at predictable and reproducible kinetics for a
predetermined period throughout the course of GI transit  and also the system that
target the delivery of a drug to a specific region within the GI tract for either a local or
systemic action. All the pharmaceutical products formulated for systemic delivery via
the oral  route  of  administration,  irrespective  of  the  mode of  delivery (immediate,
sustained or controlled release) and the design of dosage form (solid, dispersion or
liquid),  must  be  developed  within  the  intrinsic  characteristics  of  GI  physiology.
Therefore the scientific framework required for the successful development of an oral
drug delivery systems15.
The basic rationale for controlled drug delivery is to alter pharmacokinetic and
pharmacodynamics of pharmacologically active moieties by using novel drug delivery
systems  or  by modifying  the  molecular  structure  and/or  physiological  parameters
inherent in a selected route of administration. These cover a wide range of prolonged
action formulation which provide continuous release of their active ingredient at a
pre-determined rate at  predetermine time, reduced side effects,  etc. Drug having a
short elimination half-life, less frequent administration and better patient compliance
may be  obtained  with  sustained  release  preparation  as  compared  to  conventional
dosage form.16
Sodium alginate  beads  are  the  one  of  the  multiparticulate    drug delivery
system that are prepared to obtain prolonged or controlled drug delivery to improve
bioavailability,  stability,  and  target  to  specific  site.  Sodium  alginate  will  form
reticulated structure with crosslinking  agent like calcium ions or glutraldehyde and
this characteristic has been used to produce sustained release particulate systems for
variety of drugs 
The objective of the present study is to investigate the potential of gel beads of
drug as long terms sustain release. Famotidine is a h2 receptor antagonist; it is mainly
used  for  the  treatment  of  peptic  ulcer.  The  successful  treatment  of  peptic  ulcer  a
depends on the  maintenance of  effective  drug concentration level  in  the body for
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which a constant and uniform supply of drug is desired. As its biological half-life is
about  2  h  and  is  eliminated  rapidly,  repeated  daily  administrations  are  needed  to
maintain effective plasma levels .It shows a low and irregular bioavailability of about
50% after oral administration with a high first pass effect .It has been suggested that
drugs  with  biological  half-lives  in  the  range  of  2–8  h  are  good  candidates  for
sustained-release formulations.   Sustained release dosage forms (gel beads) deliver
the drug at a slow rate over an extended period of time and achieve this object.16
Sodium  alginate  Beads  of  famotidines  will  improve  its  bioavailability  by
bypassing  the  first  pass  metabolism because  alginate  beads  shrink  and  unable  to
swellat acidic environment and the encapsulated drugs are not released where as they
easily swell in an alkaline environment and release the drug.
A sustained-release formulation of famotidine is  available in the market  in
various  forms  which  include  Coated  granules,  and  matrix  tablets,  polyacrylate–
polymethacrylate  microspheres  prepared  by  the  solvent  evaporation  process
,microcapsules and solid dispersions of famotidine in polyvinyl pyrrolidone (PVP)-
microcrystalline  cellulose  and sustained-release  tablets  containing hydroxyl  propyl
methyl  cellulose  (HPMC)  and  cross-linked  sodium  carboxy  methyl  cellulose
(CMC)16.
Though  there  are  different  varieties  of  controlled  release  formulations  of
famotidine is available in the market, there are no much controlled release capsules of
famotidine . In this context the formulation of sodium alginate beads of Famotidine
would be useful and it will be a potential carrier for the development of controlled
release capsules which eventually will have the benefits such as reduction in dose,
related side effects, improving the stability, bioavailability and patient compliance.
The technique adopted for the development of Famotidines microbeads could
be applied for development of any other controlled release formulation using a newer
drug candidate. In the proposed method inotropic gelation we drop the mixture of
drug and polymer dispersion into aqueous calcium chloride solution, gelation occurs
instantaneously resulting to the formation of spherical micro scale sized beads, with
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narrow  particle  size,  high  yield,  low  porosity  and  optimum  sustained  release  in
various physiological gastrointestinal conditions.
Hence  the  present  study  was  planned  to  develop  and  optimize  sustained
release  oral  product  of  Famotidine  using  sodium  alginate  beads  as  hydrophilic
microbeads  carrier.  To  optimize  and  control  the  release  rate  of  drug  from  beads
various release modifiers such as HPMC H4M, carbopol 71G, pectin and  were used.
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PLAN OF WORK
STAGE I
Preformulations
• Compatibility study: Compatibility of drug with various polymers by using IR.
• Preparation of standard calibration curve.
 STAGE II  FORMULATION OF SODIUM ALGINATE MICRO BEADS BY
IONOTROPIC GELATION METHOD
• General method of formulation
• Optimization  of  process  variables  for  the  formulation  of  sodium  alginate
microbeads Preparation.
a)  Study  on  effect  of  different  concentration  of  coating  polymer  on  sodium
alginate microbeads
a) HPMC (1,1.5,1.75 and2%)
                    b) Cabapol(1,1.5,1.75 and2%)
c) Pectin(1,1.5,1.75 and2%)
STAGE III
Evaluation of prepared placebo beads
• Percentage yield
• beads size Determination
• Swelling study
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STAGE IV
Selection of optimized batches from various polymers using different ratios.
STAGE V
Preparation of drug loaded batches through optimized polymer ratio
             1)  Effect of various conc. ofdrug on optimized polymer ratio 
5mg /500mg, 10mg/500mg, 20mg/500mg and 30mg/500mg.
STAGE VI
Evaluation parameters of drug loaded beads
• Drug content
• Encapsulation efficiency
• Loose surface crystal study
• Scanning electron microscopy
• Invitro release
• Release kinetics
• order of release
• mechanism of release 
STAGE VII
Bioadhesion test of optimized batches.
STAGE VIII
Stability study of the optimized batches.
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CHEMICALS AND MATERIALS USED
Table 6.1: Chemicals and materials used
SI.
No
Materials Supplied by
1 Famotidine
Alkem pharmaceuticals Pvt Ltd,
mumbai.
2 Sodium alginate Nice chemicals, Banglore
3 Carbapol 71G
Yarrow chem Pdt
Mumbai
4
Hydroxy propyl methyl
cellulose K4M High media laboratory Pvt ltd
5 Pectin Nice chemicals, Banglore
6 Gelatin Nice chemicals, Banglore
7 Glutaraldehyde Nice chemicals, Banglore
Calcium chloride Nice chemicals, Banglore
8 Methanol Nice chemicals, Banglore
9 Potassium bromide
10 Potassium di hydrogen
orthophosphate
Nice chemicals, Banglore
11 Sodium hydroxide Nice chemicals, Banglore
12 Goat intestine Slaughter house
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INSTRUMENTS USED
Table 6.2: instruments used
SI.No Instruments Manufacturer
1 Electronic  weighing Balance Shimadzu BL220H ,Japan
2 Magnetic stirrer Remiequipmentspvt limited
2 Hot Air Oven Technico
3 Optical Microscope Dolar US 4
4 UV-Spectroscopy Shimadzu 1600, Japan
5 FTIR Shimadzu 8400,  Japan
7 Dissolution Test Apparatus Electro Lab ,TDT 08L (USP)
9 Tablet disintegration apparatus Rolex (IP/BP/USP)
Famotidine
Famotidine is a competitive, reversible inhibitor of the action of histamine at
the histamine H2-receptors, including receptors on the gastric cells. Famotidine does
not lower  serum Ca++ in hypercalcemic states. Famotidine is not  an anticholinergic
agent. 
Structure
Nomenclature: 
3-([2-(diaminomethyleneamino)thiazol-4-yl]methylthio)- N'-
sulfamoylpropanimidamide 
Molecularformula:  
C8H15N7O2S3
Molecular weight:  337.449 g/mol
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Characters: 
A white or  pale  yellow,  crystalline  powder,  freely soluble in  water  and in
methanol, sparingly soluble in ethanol, very slightly soluble in methylene chloride. It
shows polymorphism. 
Identification: 
• Dissolve 10 mg in water and dilute to 100.0 ml with the same solvent. Dilute 5.0
ml of the solution to 50.0 ml with water. Examined between 220 nm and 360 nm,
the solution shows two absorption maxima, at 229 nm and 315 nm. The ratio of
the  absorbance  measured at  the  maximum at  229  nm to  that  measured  at  the
maximum at 315 nm is 1.01 to 1.07.
• Examine by infrared absorption spectrophotometry, comparing with the spectrum
obtained with ranitidine hydrochloride CRS. Examine the substances as mulls in
liquid paraffin R. If the spectra show differences, dissolve 20 mg of the substance
to  be  examined  and  20  mg of  the  reference  substance  separately  in  5  ml  of
methanol. Evaporate to dryness in a water-bath at 40°C under reduced pressure
and with constant stirring. Dry the residues under high vacuum at 60°C for 1 h
and record new spectra using the residues. 
Tests:
Solution:
Dissolve 1.0 g in carbon dioxide-free water and dilute to 100.0 ml with the
same solvent. 
pH:
The pH of solution is 4.5 to 6.0. 
Heavy metals:
1.0 g complies with limit test for heavy metals (20 ppm). Prepare the standard
using 2 ml of lead standard solution (10 ppm Pb). 
Loss on drying: 
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Not more than 0.75 per cent, determined on 1.000 g by drying under high vacuum at
60°C. 
Sulphated ash:
Not more than 0.1 per cent, determined on 1.0 g. 
Storage:
Store in an airtight container, protected from light.
CLINICAL PHARMACOLOGY 
Pharmacokinetics: 
Absorption:  
Famotidine  is  50%  absorbed  after   oral  administration,  compared  to  an
intravenous (IV) injection with mean peak levels of 440 to 545 ng/ml occurring 2 to  3
hours after a 150-mg dose.  Propantheline slightly delays and increases peak blood
levels of Famotidine, probably by delaying gastric emptying and transit time. In one
study,  simultaneous  administration  of  high-potency antacid  (150  mmol)  in  fasting
subjects has been reported to decrease the absorption of Famotidine .
Distribution:  
The volume of distribution is about 1.4 L/kg. Serum protein binding averages
15%. 
Metabolism:  
In humans, the N-oxide is the principal metabolite in the urine; however, this
amounts  to  <4%  of  the  dose.  Other  metabolites  are  the  S-oxide  (1%)  and  the
desmethyl ranitidine (1%). The remainder of the administered dose is found in the
stool. Studies in patients with hepatic dysfunction (compensated cirrhosis) indicate
that  there  are  minor,  but  clinically  insignificant,  alterations  in  ranitidine  half-life,
distribution, clearance, and bioavailability. 
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Excretion:  
The principal route of excretion is the urine, with approximately 30% of the
orally administered dose collected in the urine as unchanged drug in 24 hours. Renal
clearance is about 410 ml/min, indicating active tubular excretion. The elimination
half-life  is  2.5  to  3  hours.  Four  patients  with  clinically significant  renal  function
impairment (creatinine clearance 25 to 35 ml/min) administered 50 mg of ranitidine
intravenously had an average plasma half-life of 4.8 hours, a ranitidine clearance of
29 ml/min, and a volume of distribution of 1.76 L/kg. In general, these parameters
appear to be altered in proportion to creatinine clearance. 
Pharmacodynamics:  
Serum  concentrations  necessary  to  inhibit  50%  of  stimulated  gastric  acid
secretion are estimated to be 36 to 94 ng/ml. following a single oral dose of 150 mg,
serum concentrations of Famotidine are in this range up to 12 hours. However, blood
levels bear no consistent relationship to dose or degree of acid inhibition.
Anti-secretary Activity 
Effects on Acid Secretion:
Famotidine inhibits both daytime and nocturnal basal gastric acid secretions as
well as gastric acid secretion stimulated by food, betazole, and pentagastrin. It appears
that  basal-,  nocturnal-,  and  betazole-stimulated  secretions  are  most  sensitive  to
inhibition by Famotidine , responding almost completely to doses of 100 mg or less,
while pentagastrin- and food-stimulated secretions are more difficult to suppress. 
Effects on Other Gastrointestinal Secretions:
Oral  Famotidine  does  not  affect  pepsin  secretion.  Total  pepsin  output  is
reduced  in  proportion  to  the  decrease  in  volume  of  gastric  juice.  And  it  has  no
significant effect on pentagastrin-stimulated intrinsic factor secretion. Famotidine  has
little or no effect on fasting or postprandial serum gastrin. 
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Other Pharmacologic Actions 
1)  Prolactin levels-no effect in recommended oral or intravenous (IV) dosage, but
small, transient, dose-related increases in serum prolactin have been reported after IV
bolus injections of 100 mg or more.  
2)  Other pituitary hormones-no effect on serum gonadotropins, TSH, or GH. Possible
impairment of vasopressin release. No change in cortisol, aldosterone, androgen, or
estrogen levels. No antiandrogenic action. 
3)  No effect on count, motility, or morphology of sperm.
Side Effects  
The following have been reported as events in clinical trials or in the routine
management of patients treated with Famotidine . The relationship to therapy with
Famotidine has been unclear in many cases. Headache, sometimes severe, seems to be
related  to  administration  of Famotidine .  Rarely,  malaise,  dizziness,  somnolence,
insomnia,  and  vertigo.  Rare  cases  of  reversible  mental  confusion,  agitation,
depression, and hallucinations have been reported, rare reports of arrhythmias such as
tachycardia,  bradycardia,  atrioventricular  block,  and  premature  ventricular  beats.
Constipation, diarrhea, nausea/vomiting, abdominal discomfort/pain, and rare reports
of  pancreatitis.  Rash,  including rare  cases  of  erythema multiforme.  Rare cases  of
alopecia and vasculitis. Rare cases of hypersensitivity reactions (e.g., bronchospasm,
fever, rash, eosinophilia), anaphylaxis, angioneurotic edema, and small increases in
serum creatinine. 
Drug Interactions 
Although Famotidine  has been reported to bind weakly to cytochrome P-450
in vitro, recommended doses of the drug do not inhibit the action of the cytochrome
P-450 linked oxygenase enzymes in the liver.  Increased or  decreased prothrombin
times  have  been  reported  during  concurrent  use  of  ranitidine  and  warfarin.  In  a
ranitidine-triazolam  drug-drug  interaction  study,  triazolam  plasma  concentrations
were higher during b.i.d. dosing of ranitidine than triazolam given alone. 
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Precautions:
General 
1. Symptomatic response to therapy with  Famotidine does not preclude the presence
of gastric malignancy. 
2. Since Famotidine is excreted primarily by the kidney, dosage should be adjusted in
patients with impaired renal  function Caution should be observed in patients with
hepatic dysfunction since Famotidine is metabolized in the liver.
3. Rare reports suggest that Famotidine may precipitate acute porphyric attacks in
patients with acute porphyria. It should therefore be avoided in patients with a history
of acute porphyria. 
4. Pregnancy Category B. This drug should be used during pregnancy only if clearly
needed. 
Famotidine  is  secreted  in  human  milk.  Caution  should  be  exercised  when  it  is
administered to a nursing mother. 
5. The safety and effectiveness of Famotidine have been established in the age group
of  1  month  to  16  years  for  the  treatment  of  duodenal  and  gastric  ulcers,
gastroesophagel reflux disease and erosive esophagitis, and the maintenance of healed
duodenzl and gastric ulcer. Safety and effectiveness in neonates (less than 1 month of
age) have not been established  
Overdose 
There  has  been  limited  experience  with  over  dosage.  Reported  acute
ingestions of up to 18 g orally have been associated with transient adverse effects
similar to those encountered in normal clinical experience In addition; abnormalities
of gait and hypotension have been reported. 
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METHODOLOGY
STAGE I: PREFORMULATION STUDIES:
i. a) Physical Drug Excipient Compatibility Studies: 
In designing a solid dosage form it is necessary to know the inherent stability
of  the  drug substance  and  possibility of  interaction  with  excipients.  The  physical
compatibility studies were coupled with the stability studies at higher temperature and
humidity conditions.  The drug excipient  compatibility study protocol  includes  the
preparation of  homogenous physical  mixture  in  1:1 ratio  of  drug and all  possible
excipients to be used in the formulation. The physical mixtures were sealed into 15ml
USP type III flint glass vials and stored in humidity chamber for 30 days at 40°C
temperature and 75% relative humidity conditions. The initial state of the mixtures
was noted and further evaluation for the possible occurrence of any interactions was
performed after the15th and 30th day.
b) Infrared spectroscopy:
Drug  excipient  compatibility  can  alter  the  physicochemical  property  and
bioavailability  of  the  drug.  This  incompatibility  thereby  affects  its  safety  and  or
efficacy.  Study  of  drug  excipient  compatibility  is  an  important  process  in  the
development of the stable dosage form and it help in the selection of right excipients.
This increases the probability of developing a stable dosage form.
Infra-red  spectroscopy  can  be  used  to  investigate  and  predict  any
physicochemical  interaction  between  different  components  in  formulation  and  to
determine the nature and extent of interaction. Therefore,  it  can be applied to the
selection of suitable, chemically compatible excipients.
The aim of the present study was to find out the possible interaction between
the selected polymers like sodium alginate, HPMC, chitosan, gelatin and pectin and
the drug famotidine   and also to identify the compatibility between the drug and the
polymers.  
1:100 ratios of sample and potassium bromide were taken in a mortar and
triturated. A small amount of triturated sample was taken into a pellet maker and was
compressed at 10kg/cm2 using a hydraulic press. The pellet was kept on to the sample
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holder  and  scanned  from  4000cm-1  to  400  cm-1  in  Shimadzu  FTIR
spectrophotometer. Samples were prepared for pure drug, pure polymer, and physical
mixture  of  drug  and  polymer.  The  spectra  obtained  through  those  samples  were
compared and interpreted for the shifting of functional peaks. 
• Preparation of calibration curve
Accurately  weighed  100  mg  of  famotidine  and  was  dissolved  in  minimum
quantity of  methanol and phosphate buffer mixture(2:1 ratio) in a 100ml volumetric
flask and make up to 100 ml with phosphate buffer pH 6.8  to get the concentration of
1mg/ ml.(stock I).This stock solution was further diluted to get  a concentration of
100µg/ml(  stock  II).Sock  II  solution  was  further  diluted  to   get  a  series  of
concentration 1-10 µg/ml.  absorbance  of  these  solution measured at  235nm in uv
spectrophotometer by taking 6.8 pH phosphate buffer as blank. Graph was plotted
concentration Vs absorbance to obtain the standard calibration curve.21
STAGE II: FORMULATION OF SODIUM ALGINATE PLACEBO MICRO 
BEADS BY IONOTROPIC GELATION AND CROSS LINKING METHOD.
• GENERAL  METHOD  OF  FORMULATION  OF  SODIUM  ALGINATE
MICRO BEADS.
Prepared 25ml of 2% solution of sodium alginate with distilled water by stirred it
with mechanical stirrer. Added this dispersion by using syringe slowly in to a beaker
containing 50ml of 2% solution of calcium chloride which was kept under continuous
agitation at 100 rpm .Allowed the beads to be formed by running the stirrer 15 min
checked the beads under microscope. Then rigidized the beads by adding 1ml of 25%
solution of glutraldehyde. Allowed the stirring for further 1 hour at 100 rpm. After
stirring for  one hour filtered the solution and collected the beads.  Obtained micro
beads were washed with water and dried at 50ºC in an oven for 1 hour. 
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Formulation Batches :
Ingredien
ts
Formulation code
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12
Famotidi
ne
10
(mg
)
20
(mg
)
30
(mg
)
40
(mg
)
10
(mg
)
20
(mg
)
30
(mg
)
40
(mg
)
10
(mg
)
20
(mg
)
30
(mg
)
40
(mg
)
Sodium
alginate
0.2
(mg
)
0.3
5
(mg
)
0.4
5
(mg
)
0.4
(mg
)
0.2
(mg
)
0.3
5
(mg
)
0.4
5
(mg
)
0.4
(mg
)
0.2
(mg
)
0.3
5
(mg
)
0.4
5
(mg
)
0.4
(mg
)
Calcium
chloride
0.2
mg
0.2
mg
0.2
mg
0.2
mg
0.2
mg
0.2
mg
0.2
mg
0.2
mg
0.2
mg
0.2
mg
0.2
mg
0.2
Mg
HPMC
K4M
0.1
mg
0.3
Mg
0.6
mg
1
mg
- - - - - - - -
Carbapol
71G
- - - -
0.1
mg
0.3
Mg
0.6
mg
1
mg
- - - -
Pectin - - - - - - - -
0.1
mg
0.3
Mg
0.6
mg
1
mg
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• OPTIMIZATION OF PROCESS VARIABLES FOR FORMULATIONS 
OF PLACEBO BEADS 
• Study on effect of different concentration of HPMC K4M as release modifier
on sodium alginate microbeads:
Four batches of placebo microbeads were prepared by using sodium alginate and
HPMC as coating polymer. To 25 ml of deionized water, 1% sodium alginate was
added and stirred with magnetic stirrer then add 1% HPMC K4M to form uniform
dispersion. The resulting dispersion was dropped through syringe with needle slowly
into a beaker containing 50 ml of 2% aqueous solution of calcium chloride which is
kept under continuous agitation at a slow speed using a magnetic stirrer. Allow the
beads  to  be  formed  by  running  the  stirrer  15  min.  Checked  the  beads  under
microscope.  Then  rigidized  the  beads  by  adding  1ml  of  25%  solution  of
glutraldehyde. Allow the stirring for further 1 hour 100 rpm. After stirring for one
hour filtered the solution and collected the beads and dried it an oven and it was coded
as  H1. By following above mentioned procedure three other batches were prepared
and were coded as H2, H3 and H4 respectively. All other variables were kept constant. 
Table 6.4: composition of placebo beads of sodium alginate coated with HPMC as
release modifier.
Formulation code Sodium alginate HPMC
H1 2.0% 1%
H2 1.75% 1.5%
H3 1.5% 2.0%
H4 1% 2.5%
• Study on effect of different concentration of Carbopol 71 g release modifier
on sodium alginate  microbeads:
Four batches of placebo microbeads were prepared by using sodium alginate and
Carbopol 71 g as coating polymer. To 25 ml of deionized water, 1% sodium alginate
was added and stirred with magnetic stirrer o form uniform dispersion .The resulting
dispersion  was  dropped  through  syringe  with  needle  slowly  into  a  beaker
containing1% Carbopol 71 g solution added 50 ml of 2% aqueous solution of calcium
chloride which is kept under continuous agitation at a slow speed using a magnetic
stirrer. Allow the beads to be formed by running the stirrer 15 min. Checked the beads
under microscope. Then rigidized the beads by addition of 1ml of 25% solution of
glutraldehyde. Allowed the stirring for further 1 hour at 100 rpm. After stirring for one
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hour filtered the solution and collected the beads and dried it an oven and it was coded
as  C1. By following above mentioned procedure three other batches were prepared
were different and coded as C2 ,C3 and C4  respectively. All other variables were kept
constant.
Table 6.5: composition of placebo beads of sodium alginate coated with Carbopol
G as release modifier. 
Formulation code Sodium alginate Carbopol G
C1 2.0% 1%
C2 1.75% 1.5%
C3 1.5% 2.0%
C4 1% 2.5%
• Study on effect of  different concentration of pectin as release modifier on
sodium alginate microbeads:
Four  batches  of  placebo  microbeads were  prepared  by using sodium alginate  and
pectin as coating polymer.  To 25 ml of  deionized water,  1% sodium alginate was
added and stirred with magnetic stirrer then add 1% Pectin to form uniform dispersion
.The  resulting  dispersion  was  dropped  through  syringe  with  needle  slowly into  a
beaker containing 50 ml of 2%  aqueous solution of calcium chloride which is kept
under continuous agitation at a slow speed using a magnetic stirrer. Allowed the beads
to be formed by running the stirrer 15 min. Checked the beads under microscope.
Then rigidized the beads by adding 1ml of 25% solution of glutraldehyde. Allow the
stirring for further 1 hour 100 rpm. After stirring for one hour filtered the solution and
collected the beads and dried it an oven and it was coded as P1. By following above
mentioned procedure three other batches were prepared and were coded as P2, P3 and
P4 respectively. All other variables were kept constant
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Table 6.6: composition of placebo beads of sodium alginate coated with Pectin as
release modifier. 
Formulation code Sodium alginate Pectin
P1 2.0% 1%
P2 1.75% 1.5%
P3 1.5% 2.0%
P4 1% 2.5%
STAGE III: EVALUATIONS OF PREPARED PLACEBO BEADS.
• Yield of production
The yields of production of micro beads of various batches were calculated using the
weight of final product after drying with respect to the initial total weight of the drug
and polymer used for preparation of microbeads and percent production yields were
calculated as per the Formula mentioned below.22
Percentage yield = (practical yield/theoretical yield) ×100
• Measurement of bead size
This  is  determined  by optical  microscopy with  the  use  of  a  calibrated  eye  piece
micrometer.
• Determination of calibration factor of stage micrometer:
For determining calibration factor 4th division of stage micrometer was coincided with
7th  division  of  eye  piece  micrometer  (one  smaller  division  of  stage  micrometer  is
equivalent to 10 micrometer)
ii)  Determination  of  particle  size  and  particle  size  distribution  by  optical
microscope
The particle size and particle size distribution of microbeads were evaluated
using optical  microscope. The dried microbeads were spread on a clean and dried
glass slide and examined on an optical microscope and size of the microbeads was
measured  by  using  the  pre-  calibrated  ocular  micrometer  and  stage  micro  meter.
About 25 particles of each formulation were observed and counted.
Mean diameter of particle size microbeads was determined by using following
formula.
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Mean size= (Σnx/ Σn× magnification value
Σnx=total number of beads× mid-point of the size range
Σn= total number of beads.
• Evaluation of swelling behaviour
Swelling behaviour was studied by measuring the percentage water uptake by the
beads.  About  50  mgof  beads  were  accurately  weighed  and  placed  in100  ml  of
phosphate buffer (pH 6.8 and 0.1 N HCl(pH 1.2). Beads were removed from their
respective swelling media after 8 h and weighed after drying thesurface water using
filter paper. The water uptake was calculated as the ratio of the increase in weight of
beads after swelling to the dry weight.23.
STAGE  IV:  SELECTION  OF  OPTIMIZED  VARIABLES  FROM  THE
PLACEBO BEADS. 
Based  on  the  physicochemical  parameters  of  the  placebo  beads  (high
percentage yield, least size of the beads, high swelling index and lowest drying rate)
the batches H1, C1& P1.
STAGE  V:   OPTIMIZATION  OF  PROCESS  VARIABLE  FOR
FORMULATION OF DRUG LOADED BEADS.
• Study on effect of  various concentration of  drug (famotidine)  on HPMC
K4M coated sodium alginate micro beads:
Accurately  weighed  quantity  of  famotidine  such  as  10  mg  was  added  to  the
selected batch of HPMC K4M coated microbeads such as H1.The resulting dispersion
was dropped through syringe with needle slowly into a beaker containing 50 ml of 2%
aqueous solution of calcium chloride which is kept under continuous agitation at a
slow speed using a magnetic stirrer. Allowed the beads to be formed by running the
stirrer  15 min.  checked  the  beads under  microscope.  Then  rigidized the beads  by
adding 1ml of 25% solution of glutraldehyde. Allowed the stirring for further 1 hour
at 100 rpm. After stirring for one hour filtered the solution and collected the beads and
dried it an oven and it was coded as FH1.
Similarly  three  other  batches  were  prepared  where;  only  the  quantity  of
Famotidine added was different such as 20mg, 30mg, and 40mg. The concentration of
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polymer was kept constant in all the batches such as 2.0% of sodium alginate and
1.0% of HPMC K4M and they were coded as FH2, FH3 and FH4 respectively.
Table 6.8: composition of Famotidine loaded sodium alginate beads coated with
HPMC K4M as release modifier. 
Formulation
code
Drug in mg/
500 mg of
Polymer
Batch selected
with HPMC as
release modifier
FH1 10 H1
FH2 20 H1
FH3 30 H1
FH4 40 H1
• Study on effect of  various concentration of  drug (famotidine)  on carbopol 71
Gcoated sodium alginate micro beads:
Accurately weighed quantity of  famotidine 5mg was  added to  the selected
batch of Carbopol 71 Gcoated microbeads such as C4. The resulting dispersion was
dropped through syringe with needle slowly into a beaker containing 50 ml of 2%
aqueous solution of calcium chloride containing carbopol 71 G solution which is kept
under continuous agitation at a slow speed using a magnetic stirrer. Allow the beads to
be formed by running the stirrer 15 min. Checked the beads under microscope. Then
rigidized the beads by adding 1ml of 25% solution of glutraldehyde. Allow the stirring
for  further  1  hour  100  rpm.  After  stirring  for  one  hour  filtered  the  solution  and
collected the beads and dried it an oven and it was coded as FC1. 
Similarly three other batches were prepared where, only the quantity of Famotidine
added was different such as 10mg, 20mg, and 30mg.The concentration of polymer
was kept constant in all the batches such as 2% of sodium alginate and 1.0 % of
Carbopol 71 G and they were coded as FC2,  FC3 and FC3 respectively.  Table 6.4:
composition  of  placebo  beads  of  sodium  alginate  coated  with  HPMC  as  release
modifier. 
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Table 6.9: composition of  famotidine loaded sodium alginate beads coated with
Carbopol 71 Gas release modifier.
Formulation
code
Drug in mg/500 mg of
polymer
Batch selected with
Carbopol 71 Gas release
modifier
FC1 10 C1
FC2 20 C1
FC3 30 C1
FC3 40 C1
• Study on effect  of   various concentration of   drug (famotidine)   on pectin
coated sodium alginate micro beads:
Accurately weighed quantity of Famotidine10 mg was added to the selected
batch of Pectin coated microbeads such as FP1.The resulting dispersion was dropped
through syringe with needle slowly into a beaker containing 50 ml of 2% aqueous
solution of calcium chloride which is kept under continuous agitation at a slow speed
using a magnetic stirrer. Allow the beads to be formed by running the stirrer 15 min.
Check the beads under microscope. Then rigidized the beads by adding 1ml of 25%
solution of glutraldehyde. Allow the stirring for further 1 hour 100 rpm. After stirring
for one hour filtered the solution and collected the beads and dried it an oven and it
was coded as FP1.
Similarly  three  other  batches  were  prepared  where,  only  the  quantity  of
Famotidine added was different such as 10mg, 20mg, and 30mg.The concentration of
polymer was kept constant in all the batches such as 2.0 % of sodium alginate and 1.0
% of Pectin and they were coded as FP2, FP3 and FP4 respectively.
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Table 6.10: composition of Famotidine loaded sodium alginate beads coated with
Pectin as release modifier.
Formulation code
Drug in mg/500mg of
polymer
Batch selected with
Pectin  as release
modifier
FP1 10 P1
FP2 20 P1
FP3 30 P1
FP4 40 P1
STAGE VI: EVALUATION PARAMETERS OF DRUG LOADED BEADS
• Estimation of drug content24
Famotidine content in the microbeads was estimated by a UV-spectrophotometric
method.  Accurately  weighed  50mg  of  microbeads  were  suspended  in  100ml  of
phosphate buffer pH 6.8The resulting solution was kept for 24hrs. Next day it was
stirred for 15min. The solution was filtered, after suitable dilution, Famotidine content
in  the  filtrate  was  analyzed  at  235nm  using  Shimadzu  1201  UV-Visible
spectrophotometer. The obtained absorbance was plotted on the standard curve to get
the exact concentration of the drug. Calculating this concentration with dilution factor
we got the percentage of actual drug content.
Estimation of encapsulation efficiency25
Drug  entrapment  efficiency  of  Famotidine  microbeads  was  performed  by
accurately  weighing  50mg of  microbeads  and  suspended  in  100  ml  of  phosphate
buffer pH6.8 and it was kept on a side for 24 hours. Then, it was stirred for 15 mins
and filtered. After suitable dilution, Famotidine content in the filtrate was analyzed
Spectrophotometrically at 235 nm using shimadzu 1201 U.V. Spectrophotometer. The
obtained absorbance was plotted on the standard curve to get the exact concentration
of the entrapped drug. Calculating this concentration with dilution factor we got the
percentage of actual drug encapsulated in microbeads. The drug entrapment efficiency
was determined using following relationship.
% Drug entrapment efficiency =   Actual drug content x 100
                                                                         Theoretical drug content
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• Loose surface crystal study (LSC)24
This study was conducted to estimate the amount of drug present on the surface of
the  microbeads  which  showed  immediate  release  in  dissolution  media.  100mgof
microbeads were suspended in 100ml of phosphate buffer (pH 6.8), simulating the
dissolution media. The Samples were shaken vigorously for 15min in a mechanical
shaker.  The  amount  of  drug  leached  out  from  the  surface  was  analyzed
spectrophotometrically  at  235nm.  Percentage  of  drug  released  with  respect  to
entrapped drug in the sample was recorded. 
• Scanning electron microscopy analysis (SEM)26
The  shape  and  surface  characteristics  were  determined  by  scanning  electron
microscopy  (model-JSM,  35CF,  jeol,  Japan)  using  gold  sputter  technique.  The
particles were vacuum dried, coated to 200 Ao thicknesses with gold palladium using
prior  to  microscopy.  A  working  distance  of  20nm,  a  tilt  of  zero-degree  and
accelerating voltage of 15kv were the operating parameters. Photographs were taken
within a range of 50-500 magnifications.
• In-vitro release studies 27
In-vitro  release  studies  of  prepared  microbeads  were  carried  out  using  phosphate
buffer (pH 6.8) using USP- basket type apparatus.Accurately weighed quantity of 250
mg of prepared microbeads put into the basket rotated at a constant speed at 100rpm
and maintained temperature 37±5ºC in 900ml of the dissolution medium (phosphate
buffer H6.8).The sample was withdrawn at 0.5hrs,1hrs, 2hrs, 3hrs, 4hrs, 5hrs, 6hrs,
7hrs, 8hrs, 9hrs, 10hrs, 11hrs, 12hrs, 14hrs, 18hrs, and 24hrs. Each time interval 5 ml
of sample was withdrawn, at the same time 5 ml of fresh dissolution media was added
to  maintain  sink  condition.  The  withdrawn  samples  were  suitably  diluted  and
measured  the  absorbance  at  235  nm  Spectrophotometrically.Then  calculated  the
cumulative percentage drug release at regular time intervals.
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STAGE  VII:  IN  VITRO  RELEASE  KINETIC  STUDY  ON  SELECTED
BATCHES OF FAMOTIDINE BEADS.
i) Determination of order of release of drug (Famotidine) from micro beads by
graphical method.
To determine  the  order  of  release  of  drug from micro  beads  by graphical
method from the dissolution data,  a graph was plotted with % drug remaining Vs
time. Zero order release can be confirmed if straight or linearity is obtained. To find
out the release rateconstant, the slope of the curve was found out and multiplied with
2.303. Regression coefficient of the curve was determined to confirm the correlation
between X and Y axis.
In the second stage, using the same dissolution data, a graph was plotted with
log% remaining Vs time. If a straight line or linearity is observed, it can be confirmed
that the drug release follow first order kinetics. The slope of the graph was found out
and  multiplied  with  2.303  to  obtain  the  first  order  rate  constant  k1.  Regression
coefficient of the graph was fount out to confirm the correlation between X and Y
axis.
•   Study on mechanism of drug release 
In  order  to  predict  and  correlate  the  release  behavior  of  drug  from  the
polymeric matrix, it is necessary to fit the invitro release data in to a suitable model.
Hence  the  dissolution  data  were  fitted  according  to  the  well-known  exponential
equation, which is often used to describe the drug release behavior from a polymer
system. The equation which is used to describe drug release mechanism is:      
Mt / Mα =ktn
Where, Mt  / Mα is the fraction release of the drugs’ is the release time, ‘k’ is
the constant, which indicate the properties of the macromolecular polymeric system,
and ‘n’ is the release exponent indicative of the mechanism of release. The ‘n’ value
was used for the analysis of drug release mechanism from drug loaded micro beads.
The  ‘n’ values  were  determined  for  all  batches  of  drug  loaded  micro  beads  by
graphical method, which is explained below.  
In the first stage, a graph plotted with log% release Vs log time. If a straight line is
obtained,  then  the  regression  coefficient  was  found  out  to  confirm  the  linearity
between Xand Y. The slope (n) of the line was found out and if 
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n≤0.5 : The release is by Fickian diffusion
n>0.5 and<1   : The release mechanism is swelling
n =1                 : Release is by case II transport release   mechanism
n>1                  : Release is by Super case II Transport
 In the second stage, a graph was plotted with % release Vs √time. If linearity
is observed, the release mechanism is by Higuchi’s diffusion.
STAGE IX:  STABILITY STUDIES FOR BEST FORMULATION 24
To assess the long term physical stability, micro beads from selected batches
(FH3 and FC3) were filled into a hard gelatin capsules manually and wrapped the filled
capsule with aluminum foil, and put this entire packet in to self-sealing polyethylene
cover. The studies were performed at room temperature for period of 45 days. Change
in Particle size distribution with optical microscope and change in drug content by
Spectrophotometrically at 235 nm was calculated every 7 days for the entire period of
stability study.
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STAGE I
PRE-FORMULATION STUDIES:
Infrared spectroscopy
The compatibility of the drug and formulation is an important pre-requisite for
formulation. An IR spectroscopic analysis was carried out to check the compatibility
between the polymers and selected drug FAMOTIDINE. IR spectrum was obtained
through pure polymer, pure drug, and drug- polymer physical mixture. These entire
spectra  were  checked  for  shifting  for  major  functional  peaks  and  also  they were
observed for the appearance of new characteristic peaks.
The IR  spectrum of FAMOTIDINE showed the peaks 35051.69 cm-1  (N-H
stretching, amides), 3376.67cm-1 (N-H asymmetric, sulphonamide), 3103.86cm-1 (C-H
stretch),  1331.03cm-1 (Asymmetrical  SO2 stretching),  1171.3cm-1  (symmetrical  SO2
stretching)  and  902.07  cm-1 S-N  stretching.  These  peaks  can  be  considered  as
characteristic  peaks  of  FAMOTIDINE  and  were  not  affected  and  prominently
observed in IR spectra of FAMOTIDINE along with polymers as shown in Fig.1-
Fig10. The spectra indicated no interaction between FAMOTIDINE and polymers.
IR spectrum of sodium alginate showed the characteristic peaks at  3176.76
cm−1  (OH−  stretching)  1596  and1407  cm−1  (COO−  asymmetric  and  symmetric
stretching),  1081-1024 cm−1  (C-O-C anti  symmetric  stretching),  and  carboxyl  and
carboxylate  at  about  1000  to  1400  cm−1.  These  peaks  can  be  considered  as
characteristic peaks of sodium alginate. 
Infrared absorption spectrum of HPMC K4M (figure 7.3) shows all prominent
7peaks. IR spectrum indicated characteristics peaks belonging to measure functional
groups such as principal peaks at wave numbers 2922.59, 3420.14, 1058.73, 1640.16
cm-1. The major IR peaks observed in HPMC were 2922.59 (2850 – 3000) (C-H),
3420.14 (3300 – 3500) (NH), 1058.73 (1000 – 1300) (C-O) cm-1.
An IR spectrum of Carbopol 71 G the peak at  3458.37 cm-1 corresponds to
stretching  vibrations  of  hydroxyl  group  in  Carbopol  71  G.  The  backbone  of  the
polymer is manifested through peak at 2925cm-1 C-H aliphatic stretching vibrations.
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The stretching vibrations of C O are found at 1716 cm-1. Also C-H bending (CH2) at
1450.47 cm-1 can also be observed.
FTIR  spectra  of  pectin  samples  showed  characteristic  peaks  at  3388.93,
2895.0, 1747.0 and 1053.13cm−1 corresponding, respectively, to –OH, –CH, C O of
ester and acid, and –COC– stretching of the galactouronic acid.
The presence of same peak which are characteristic functional group of the
FAMOTIDINE  and  polymers  like  sodium alginate,  HPMC,  Carbopol  71  G  and
Pectin are present in the drug polymer physical mixture confirm that there is no major
shifting in the functional peak and there is no appearance of new characteristic peaks.
There  is  no  interaction  between  drug  FAMOTIDINE  and  polymers  like  sodium
alginate, HPMC, Carbopol 71 G and Pectin. Hence the selected drug FAMOTIDINE
is found to be compatible with the selected polymers like sodium alginate, HPMC,
Carbopol 71 G and Pectin.                                             
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Figure7.1 IR spectrum of FAMOTIDINE
Figure 7.2 IR spectrum of sodium alginate
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Figure 7.3 IR spectrum of HPMC K4M
                                                                  
Figure 7.4 IR spectrum of carbapol
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Figure 7.5 IR spectrum of pectin
                      
Fig  7.6  IR  spectrum  of  sodium  alginate,  carbapol–  FAMOTIDINE  physical
mixture
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Fig 7.7 : IR spectrum of sodium alginate, pectin – FAMOTIDINE physical
mixture
Fig 7.8 IR spectrum of Sodium alginate, – FAMOTIDINE physical mixture
Dept. of Pharmaceutics 81 JKKMMRF College of Pharmacy
Chapter 05                                                                                                Result and 
Discussion
ii) Development of solubility profile of selected drug (FAMOTIDINE) in various
solvent used particles making procedure.
To know the solubility of the selected drug in polar, non- polar solvents and phosphate
buffer, the solubility test was done in various organic solvents, distilled water and
phosphate buffers. From the table (1) it is clear that the selected drug FAMOTIDINE
is freely soluble in alcoholic solution, buffer solution and poorly soluble in water. 
iii) Preparation of calibration curve:
Prepared  calibration  curve  of  drug  FAMOTIDINE  by  using  phosphate  buffer
(pH6.8).The  drug  absorbance  was  measured  at  235  nm  using  UV  double  beam
spectrophotometer.  The  linearity  of  the  absorbance  was  found  to  be  from  the
concentration between 2-10µg/ml (r2=0.9934).
Table 7.2: calibration data of drug FAMOTIDINE by using phosphate buffer pH
6.8
Concentration in
µg/ml
Absorbance at
235 nm
0 0
2 0.156
4 0.259
6 0.392
8 0.519
10 0.653
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Figure 7.11: Calibration curve of drug FAMOTIDINE by using phosphate buffer
pH6.8
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STAGE II: FORMULATION OF SODIUM ALGINATE MICRO BEADS BY
IONOTROPIC GELATION AND CROSSLINKING METHOD.
I. General method of formulation of sodium alginate micro beads.
Micro beads prepared by ionotropic gelation and cross linking method. In this
study micro beads were prepared by using sodium alginate alone and calcium chloride
used as counter ion.
II. Optimization of process variables.
a) study on effect of different concentration of HPMC K4M as release modifier  
on  sodium alginate micro beads:
Four batches of micro beads coded such as (H1,  H2, H3  and H4) were prepared by
using sodium alginate and HPMC as coating polymer and they were evaluated for
their  percentage yield,  drying rate,  shape and size distribution through the optical
microscope and swelling ratio. 
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Table (7.3) shows the effect of concentration of HPMC on beads formation.
Formulation
code
%
yield
Beads size in
µm Shape
Swelling
ratio
S 98 1249.5±2.3 Discrete beads 1810.6±2.1
H1 95 1116.2±1.1 Discrete beads 1875.4±0.9
H2 94 1148.5±1.8 Discrete beads 1723.6±3.4
H3 93 1167.4±1.6 Aglomerate beads 1698.6±2.4
H4 91 1204±3.7 Aglomerate beads 1497±1.23
The percentage yields were in the range between 91-95%. The yields were slightly
increased  by  increasing  the  concentration  of  sodium  alginate  and  decreasing  the
concentration of HPMC K4M.                                
Figure 7.12 shows the effect of HPMC K4M on % yield
S H1 H2 H3 H4
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100
%  YIELD
%  yield %  yield
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Figure7.14 shows the effect of HPMC K4M on beads size
Swelling ratios was found to be in the range of 1497- 1810%. Swelling ratios were
more by decreasing the concentration of coating polymer like HPMC K4M.
Figure7.15 shows the effect of HPMC K4M on swelling ratio
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 Based on the high percentage yield, more swelling ratio, least size and good shape,
micro beads prepared with 2% sodium alginate and 1% HPMC as release modifier
coded as H1 was selected for drug loading.          
Dept. of Pharmaceutics 86 JKKMMRF College of Pharmacy
Chapter 05                                                                                                Result and 
Discussion
b) Study  on  effect  of   different  concentration  of  Carbopol  71  G  as  release
modifier  on  sodium alginate micro beads:
Four batches of micro beads coded such as (C1, C2, C3 and C4) were prepared by using
sodium alginate and Carbopol 71 G as coating polymer and they were evaluated for
their  percentage yield,  drying rate,  shape and size distribution through the optical
microscope and swelling ratio. 
Table 7.4 shows the effect of concentration of Carbopol 71 G on beads formation.
Formulati
on code
%
yield
Beads  size
in µm
Swelling
ratio
Shape of beads
C4 84 1257±3.1 1465±0.7 Aglomerate beads
C3 85 1249.6±1.9 1496±0.8 Aglomerate beads
C2 87 1215±2.37 1685±1.4 Discrete beads
C1 91 1138.8±1.9 1725±2.7 Discrete beads
The percentage yields were in the range between 84-91%. The yields were slightly
increased  by  increasing  the  concentration  of  sodium  alginate  and  decreasing  the
concentration of Carbopol 71 G.
Figure7.17 shows the effect of Carbopol 71 G on % yield
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Beads shape and size distribution were found to be in the range of 1.1- 1.2
mm. Beads were clumped by increasing the concentration of coating polymer like
Carbopol 71 G.                               
Figure7.19 shows the effect of Carbopol 71 G on beads size
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Swelling ratio was found to be in the range of 1464- 1720%. Swelling ratio were more
by decreasing the concentration of coating polymer like Carbopol 71 G.   
Figure7.20 effect of Carbopol 71 G on swelling ratio
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Based on the high percentage yield, more swelling ratio, least size and good shape,
and lowest drying rate micro beads prepared with 1.75% sodium alginate and 0.25%
Carbopol 71 G as release modifier coded as C4 was selected for drug loading.
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c) study on effect of different concentration of   pectin as release modifier on
sodium alginate micro beads
Four batches of micro beads coded such as (P1,  P2, P3 and P4) were prepared by using
sodium alginate  and  Pectin  as  coating  polymer  and they were  evaluated  for  their
percentage  yield,  drying  rate,  shape  and  size  distribution  through  the  optical
microscope and swelling ratio.                    
                   Table 7.5 effect of concentration of Pectin on beads formation.
Formulati
on code
%  yield Beads size in
µm
Drying
rate/hr.
at 50ºC
Swelling ratio Shape of beads
P4 74 1398.44±1.2 3.15 943+0.9 Aglomerate
beads
P3 74 1379.9±1.9 2.45 1082+1.2 Aglomerate
beads
P2 75 1246±1.2 2.10 1235+1.5 Discrete beads
P1 79 1201.23±0.8 1.45 1449+1.1 Discrete beads
The percentage yields were in the range between 73-78%. The yields were slightly
increased  by  increasing  the  concentration  of  sodium  alginate  and  decreasing  the
concentration of Pectin.                                     
Figure7.22 effect of Pectin on % yield
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                                  Figure 7. effect of Pectin on beads size
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Swelling ratio was found to be in the range of 940-1444%. Swelling ratio were more
by decreasing the concentration of coating polymer like Pectin.       
                              Figure 7.25  effect of Pectin on swelling ratio
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Based on the high percentage yield, more swelling ratio, least size and good
shape, and lowest drying rate micro beads prepared with 2.0% sodium alginate and
1.0% Pectin as release modifier coded as P1 was selected for drug loading.
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STAGE  III:  SELECTION  OF  OPTIMIZED  VARIABLES  FROM  THE
PLACEBO BEADS.
Based  on  the  physicochemical  parameters  of  the  placebo  beads  (high  percentage
yield,  least  size  of  the  beads,  highest  swelling  index  and  lowest  drying  rate)  the
batches H4, C 4, P4 and G 4 have been selected for drug loading.
STAGE  IV:  OPTIMIZATION  OF  PROCESS  VARIABLE  FOR
FORMULATION OF DRUG LOADED BEADS.
i) Study on effect of   various concentration of  drug (Famotidine) on HPMC
K4M coated sodium alginate micro beads:
Four different concentration of Famotidine such as 10mg, 20mg, 30mg and 40
mg was added to the optimized batch of polymer coded as FH1  and they  were  coded
as FH4, FH3, FH2 and FH1  respectively and they were evaluated for their drug content,
entrapment efficiency, loose surface crystal study and in vitro release study. The result
showed that the highest percentage of drug content, entrapment efficiency and loose
surface crystals were found to be produced by batch  FH2. Lowest    percentage of
drug  content,  entrapment  efficiency  and  loose  surface  crystals  were  found  to  be
produced by batch FH4                     
Table  (7.7)  shows the  effect  of  concentration  of  drug on  HPMC K4M beads
formation.
Formulation
code
Amount 
Drug in mg/ 
500mg of 
polymer
Beads
size in
mm
Swelling
ratio at
pH 6.8
Swelling
ratio at
pH 1.2
Entrap
ment
efficiency
(%)
LSC
(%)
FH4 40 1214±1.5 1724 182 82.23+1.6 1.113
FH3 30 1252±1.8 1730 192 87.97+1.7 1.949
FH2 20 1182±0.9 1736 212 92.76+0.5 4.300
FH1 10 1212±1.3 1757 214 93.57+0.4 4.34
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Figure7.32 effect of concentration of drug on % entrapment of HPMC coated
beads.
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  The in vitro release study of famotidine from micro beads were studied at 37
±0.5ºC using phosphate buffer (pH 6.8) as the release medium. In vitro dissolution
profiles of all the batches (FH1, FH2, FH3 and FH4) were studied for 24 hrs. The
batch FH1
 
showed better sustained effect compared to other three batches.
In  vitro dissolution  studies  of  Famotidine  microbeads  prepared  by  using
HPMCK4M.
Name of the drug                                      Famotidine
Dissolution medium                                  phosphate buffer pH6.8
Vol. of dissolution medium 900ml
Volume of sample withdrawn                   5ml
Slope of calibration curve                         0.064
R2 of calibration curve                              0.9934
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Table: 7.8 Cumulative percentage releases of micro beads prepared with sodium
alginate and HPMC K4M as release modifier.
Time in 
hours
Cumulative percentage of drug release
FH1 FH2 FH3 FH4
0.25 15.45 2.761 - 7.37
0.5 19.65 6.126 2.421 9.966
1 22.40 7.26 14.816 13.878
2 24.67 8.94 21.36 15.87
3 27.43 11.84 33.87 22.13
4 31.76 19.87 49.68 31.34
5 38.45 25.69 65.12 32.178
6 44.23 32.67 84.34 32.99
7 49.56 39.78 94.10 38.81
8 51.56 47.89 104.79 47.89
9 59.57 60.45 52.56
10 63.56 78.90 63.04
11 67.34 90.45 69.87
12 74.67 98.34 79.55
14 81.34 87.67
16 84.56 96.56
20 94.23
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Figure7.33:  In vitro  dissolution  profile  of  micro beads prepared with sodium
alginate and HPMC K4M as release modifier.
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Study on effect of  various concentration of  drug (Famotidine)  on Carbopol 71 
G coated sodium alginate micro beads: 
Four different concentration of Famotidine such as 10mg, 20mg, 30mg and
40mg was added to the optimized batch of polymer coded as C4  and they  were  coded
as FC4 FC3,  FC2 and FC1  respectively and they were evaluated for their drug content,
entrapment efficiency, loose surface crystal study and in vitro release study. The result
showed that the highest percentage of drug content, entrapment efficiency and loose
surface crystals were found to be produced by batch FC2. Lowest percentage of drug
content, entrapment efficiency and loose surface crystals were found to be produced
by batch FC4                         
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Table (7.9) effect of different concentration of drug on Carbopol 71 G coated 
beads formation.
Formulatio
n
Code
Amoun
t Drug
in mg/
500mg
of
polyme
r
Beads
size in
mm
Swellin
g ratio
at pH
6.8
Swellin
g ratio
at pH
1.2
Entrapme
nt
efficiency
(%)
LS
C
(%)
FC1 40 1017±1.7 2541 213 83.73+0.43 0.1
9
FC2 30 1006.3±2.
1
2381 244 96.49+1.05 0.2
1
FC3 20 997.6±1.5 2185 153 88.18+0.43 0.1
5
FC4 10 973±2.2 1910 172 82.46+0.31 0.1
4
                    Figure7.34 effect of concentration of drug on % entrapment
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In vitro dissolution study:
The in vitro release study of famotidine from micro beads were studied at 37
±0.5ºC using phosphate buffer (pH 6.8) as the release medium.In vitro dissolution
profiles of all the batches (FC4, FC3, FC2 and FC1) were studied for 24 hrs. The batch
FC2
 
showed better sustained effect compared to other three batches.
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In vitro dissolution studies of Famotidine microbeads prepared by using 
Carbopol 71 G.
Name of the drug                                      Famotidine
Dissolution medium                                  phosphate buffer pH6.8
Vol. of dissolution medium 900ml
Volume of sample withdrawn                   5ml
Slope of calibration curve                         0.064
R2 of calibration curve                              0.9934
Table: 7.10 Cumulative percentage releases of micro beads prepared with sodium
alginate and Carbopol 71 G as release modifier
Time in 
hours
Cumulative percentage of drug release
FC4 FC3 FC2 FC1
0.25 - - - 0.156
0.5 - - 0.213 1.1345
1 3.34 0.581 0.988 6.786
2 4.517 3.24 3.137 8.678
3 12.623 10.12 7.567 11.678
4 52.75 16.24 40.23 38.81
5 66.73 35.52 59.78 49.34
6 93.66 52.66 62.67 58.87
7 67.12 69.46 67..90
8 73.67 75.67 69.67
9 80.12 79.23 81.56
10 88.75 83.43 85.83
11 96.08 87.67 96.78
12 91.07 99.02
Dept. of Pharmaceutics 97 JKKMMRF College of Pharmacy
Chapter 05                                                                                                Result and 
Discussion
Figure 7.35: In vitro dissolution profile of micro beads prepared with sodium 
alginate and Carbopol 71 G as release modifier
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Study on effect of  various concentration of  drug (Famotidine)  on pectin coated
sodium alginate micro beads:
Four different  concentration of  Famotidine  such as  5mg,  10mg,  20mg and
30mg was added to the optimized batch of polymer coded as P4  and they  were  coded
as F9,  F10,  F11 and F12  respectively and they were evaluated for their drug content,
entrapment efficiency, loose surface crystal study and in vitro release study. The result
showed that the highest percentage of drug content, entrapment efficiency and loose
surface crystals were found to be produced by batch F12. Lowest percentage of drug
content, entrapment efficiency and loose surface crystals were found to be produced
by batch F9.                   
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Table (7.11) shows the effect of different concentration of drug on pectin coated 
beads formation.
Formulation
Code
Amount
Drug in
mg/ 500mg
of polymer
Beads
size in
mm
Swelling
ratio at pH
6.8
Swelling
ratio at pH
1.2
Entrapment
efficiency
(%)
LSC
(%)
FP4 40 1398±0.8 2214 221 78.16+1.84 1.949
FP3 30 1252±1.7 2298 236 79.91+1.2 1.113
FP2 20 1375±1.5 2331 245 85.26+0.58 4.300
FP1 10 1201±1.4 2364 244 98.12+0.33 4.34
Figure7.36 shows the effect of concentration of drug on % entrapment
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The in vitro release study of famotidine from micro beads were studied at 37
±0.5ºC using phosphate buffer (pH 6.8) as the release medium. In vitro dissolution
profiles of all the batches (FP1, FP2, FP3 and FP4) were studied for 24 hrs. The batch
FP1 showed better sustained effect compared to other three batches.
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In vitro dissolution studies of Famotidine microbeads prepared by using Pectin.
Name of the drug                                      Famotidine
Dissolution medium                                  phosphate buffer pH6.8
Vol. of dissolution medium 900ml
Volume of sample withdrawn                   5ml
Slope of calibration curve                         0.064
R2 of calibration curve                              0.9934
Table: 7.12 Cumulative percentage releases of micro beads prepared with sodium
alginate and Pectin as release modifier
Time in 
hours
Cumulative percentage of drug release
FP1 FP2 FP3 FP4
0.25 5.118 13.58 24.48 31.33
0.5 10.04 18.61 33.57 41.11
1 15.53 27.207 38.82 49.25
2 18.42 33.41 46.43 52.23
3 25.73 43.27 52.13 55.21
4 36.42 52.36 61.11 57.21
5 41.42 63.92 72.077 59.24
6 49.01 72.18 75.92 63.19
7 49.09 77.15 76.13 67.16
8 56.87 94.42 78.69 69.16
9 57.94 97.218 86.39 78.06
10 60.29 98.28 88.31 86.01
11 58.82 88.69 97.90
12 62.92 93.54
14 65.79 96.39
18 73.91 99.24
24 98.64
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Figure 7.37 In vitro dissolution profile of micro beads prepared with sodium 
alginate and Pectin as release modifier
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STAGE VII: IN VITRO RELEASE KINETIC STUDY ON SELCTED BATCH
OF SODIUM ALGINATE MICROBEADS LOADED WITH FAMOTIDINE.
All the release data was fitted into various kinetic models like, zero order, first
order, Higuchi, and Korsmeyer-Peppas, in order to find out order and mechanism of
drug release from polymeric spheres.
Determination of order of release
Determined the order of release of drug from the selected batch of microbeads
by graphical  method from the dissolution data,  a  graph was  plotted with % drug
release remaining Vs time to find out zero order release. Linearity was observed and
results are shown in the table ( 7.15 ) and figure (7.38-7.41 )                                     
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Figure 7.40: order release of batch FH1
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Figure7.41: order of release of batch FC2
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Figure7.42: order of release of batch FP1
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Figure 7.43: order of release of batch F15
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The result  showed that  all  the selected batches  of  microbeads  loaded  with
famotidine (FH1, FC2, and FP1) followed zero order release.
Mechanism of release.
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Determined the order of release of drug from the selected batch of microbeads
by graphical  method from the  dissolution data,  a  graph  was  plotted with % drug
release Vs square root of time to find out higuchi diffusion mechanism and log % of
release Vs log time to find out korsmeyer Peppas’s.
The value of ‘n’ gives an indication of the release mechanism; when n = 1, the
release rate is independent of time (zero-order) (case II transport), n = 0.5 for Fickian
diffusion and when 0.5 < n <1.0, diffusion and non-Fickian transport are implicated.
Lastly, when n > 1.0 super case II transport is apparent. Regression coefficient and ‘n’
were calculated and is given in Table: (7.15) From the table, the value showed that,
prepared  micro  beads  exhibited  zero  order  kinetics  followed  by  super  case  -II
transport.
Korsmeyer Peppas’s. Graphs were plotted for selected batches (F1, F2, F3 and F
4) and ‘n’ value was found to be > 1. Therefore the mechanism was found to be super
case II transport. 
Figure 7.44: mechanism of release of batch FH1
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Figure7.45: Mechanism of release of batch FC2
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Figure 7.47: Mechanism of release of batch FP1
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Table 7.15: model fitting data for in-vitro releases kinetic parameters of micro 
beads loaded with Famotidine. 
Formulatio
n code
Zero order
(R2)
Rate
constant
(K)
Korsmeyer
peppas ( R2) ‘n’ values
FH1 0.993 4.822 0.923 1.351
FC2 0.923 8.890 0.957 0.491
FP1 0.953 4.048 0.984 1.148
STAGE VII:  STABILITY STUDIES FOR BEST FORMULATION
In order to find out the stability of the drug loaded micro beads , selected and
optimized batches of micro beads from each polymer  containing known percentage
of drug loading was stored at room temperature and it was observed for 45 days. The
change in drug content was determined at an interval of 7 days. The morphology of
the micro beads was also observed through optical microscope. Table (7.17) showed
that the micro beads were stable at room temperature. The stability study revealed that
there was no change in morphology and no change in drug content.
TABLE 7.16: Stability studies
TIME
IN
DAYS
BEADS SIZE IN µM %ENTRAPMENT
FH1 FC2 FP1 FH1 FC2 FP1
7 1172.5±1.1 1256±2.3 1089.2±1.4 90.57+0.5 82.73+0.4 99.1±0.3
15 1172.5±1.3 1256±2.1 1089.2±1.2 90.57+0.6 82.73+0.4 99.1±0.9
22 1172.5±0.3 1256±2.5 1089.2±0.9 90.57+0.7 82.73+0.4 99.1±0.7
30 1172.5±1.2 1256±2.1 1089.2±0.6 90.57+1.5 82.73+0.1 99.1±0.9
37 1172.5±1.48 1256±2.43 1089.2±0.9
90.57+0.5
2
82.73+0.4
9 99.2±1.1
45 1172.5±1.23 1256±1.35 1089.2±0.6
90.57+0.5
4
82.73+0.5
3 99.1±0.5
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Time
in
days
Evaluated parameters
Beads size in µm % entrapment
FH2 FC2 FP4 FH2 FC2 FP4
7 1172.5±1.1 1256±2.3 1089.2±1.
4
90.57+0.5 82.73+0.4 99.1±0.3
15 1172.5±1.3 1256±2.1 1089.2±1.
2
90.57+0.6 82.73+0.4 99.1± 0.9
22 1172.5±0.3 1256±2.5 1089.2±0.
9
90.57+0.7 82.73+0.4 99.1± 0.7
30 1172.5±1.2 1256±2.1 1089.2±0.
6
90.57+1.5 82.73+0.1 99.1± 0.9
37 1172.5±1.48 1256±2.4
3
1089.2±0.
9
800.8±1.
2
90.57+0.52 82.73+0.49 99.2± 1.1
45 1172.5±1.23 1256±1.3
5
1089.2±0.
6
800.8±1.
5
90.57+0.54 82.73+0.53 99.1± 0.5
Scanning electron microscopy (SEM)
The morphological evaluation of the optimized micro beads formulation coded
as FH1 was done by scanning electron microscopy (Figure). SEM study revealed that
the microbeads were almost spherical in shape with rough outer surface.
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Figure 7.49 shape and size of the beads (FH1)
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SUMMARY AND CONCLUSION
In  the  present  study  an  attempt  was  made  to  formulate  sustained  release
microbeads of Famotidinefrom sodium alginate with different release modifiers such
as HPMC K4M, Carbopol 71G and Pectin so as to enhance bioavailability and to
reduce dosing frequency of the selected drug.
• The goal of any drug delivery system is to provide a therapeutic amount of drug to
the proper site in  the body and also to achieve and maintain the desired drug
concentration. This could be achieved through Multiparticulate dosage like beads
which is divided into many individual units, so-called subunits, each exhibiting
some desired characteristics.
• An  attempt  is  made  to  develop  microbeads  by Ionotropic  Gelation  and  cross
linking Technique with a view to improve bioavailability, and also to reduce dose
frequency and  thereby to achieve an oral controlled release of the drug. 
• .From  FT IR  study,  it  was  concluded  that  there  was  no  interaction  between
polymers and drug. All the polymers used were compatible with the drug. 
• Placebo beads were prepared by Ionotropic gelation and cross linking method by
Using Sodium alginate and various types of different concentration of hydrophilic
polymers  such  as  HPMC  K4m,  Carbopol,  and  Pectin   as  release  modifiers,
Calcium chloride as counter ion and glutraldehydeas cross-linking agent. Sixteen
batches  of  placebo  micro  beads  were  prepared  with different  concentration of
polymers and they were coded such as H1, H2, H3, H4, C1, C2, C3, C4, P1, P2, P3, P4,
G1, G2, G3 and G4.
• All  the  prepared  placebo  beads  were  subjected  to  evaluation  parameters  like
percentage yield, Particle size analysis, drying rate study and Swelling behavior.
• Percentage yield of beads were found in the range of 73-95% 
• Particle size of gel beads were found in the range of 1103±0.8 to1399±1.2µm.
• Swelling index of gel beads were in range of 940±0.9 to 1874 ±3.4 %
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• Based on the highest  percentage yield,  and least  beads size and high swelling
index, few batches were selected for drug loading. Batches with 2% of sodium
alginate and 1% of release modifier like HPMC K4M, Carbopol and Pectin.
• Drug loaded beads were prepared by same method and same polymer but only the
difference  was  the  concentration  of  drug  FAMOTIDINE.  Four  different
concentration of drug Famotidinesuch as 10mg, 20mg, 30mg & 40mg were added
to the optimized batch of polymers. 
• All the drug loaded beads were subjected to evaluation parameters like percentage
drug entrapment, loose surface crystal study and in vitro release study. Based on
the  highest  Percentage  entrapment,  more  loose  surface  crystals  and  better
sustained effect, the batches, like  FH1,  FC2  & FP1  were found  to be better than
other  batches.
• Selected batch such as  FH1,  FC2  & FP1  weresubjected to  in vitro release kinetic
study, stability study and was found to exhibit zero order kinetics with release
mechanism of super caseII-transport and they were found to be stable when stored
at room temperature for 45 days
• Scanning  electron  microscopic  study  of  selected  batch  FH1 was  found  out  and  it
revealed that  the microbeads were almost  spherical  in  shape with rough outer
surface.
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CONCLUSION
In conclusion, ionotropic gelation and cross linking technique can be used for
preparations  of  Famotidinemicro  beads  from  sodium  alginate  with  other  release
modifiers like HPMC K4M, Carbopol 71G and Pectin. Prepared microbeads showed
higher  drug  entrapment  and  prolonged  release  characteristics.  Famotidine  release
from micro beads was influenced by the proportion of alginate and release modifiers..
The beads formed have a spherical shape with rough surface as evidenced by SEM.
The  result  of  in  vitro release  and  release  kinetic  indicated  sustained  release  and
exhibited zero order kinetic followed by super caseII- transport. Therefore, one can
assume that the Famotidine micro beads are promising pharmaceutical dosage forms
by providing sustaining effect  and thereby improving the bioavailability.  Therefore
this developed sodium alginate micro beads with release modifier could be used as a
carrier for the sustained delivery of other categories of drugs. The entire process is
feasible in an industrial scale and demands pilot study.
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